Office de la propriété intellectuelle du Canada
organisme d'Industrie Canada
www.opic.gc.ca

Canadian Intellectual Property Office
An Agency of Industry Canada
www.cipo.gc.ca

(11) (C) **1,341,503**

(21) 554,561

(22) 1987/12/16

(45) 2006/04/04

(52) 195 - 1.20
CL CR. 195 - 1.35
530 - 13.00
195 - 122.6

(51) Int.Cl. ***C12N 15/24*** (2006.01), ***C12N 15/63*** (2006.01), ***C07K 14/54*** (2006.01), ***C07K 16/24*** (2006.01), ***C12P 21/02*** (2006.01), ***A61K 38/20*** (2006.01), ***A61P 7/00*** (2006.01)

(19) (CA) **CANADIAN PATENT** (12)

(54) Molecular Cloning and Expression of Human IL-3

(72) DORSSERS, LAMBERTUS CHRISTIAAN JOHANNES, NETHERLANDS
WAGEMAKER, GERARD, NETHERLANDS
VOS, YVONNE JOHANNA, NETHERLANDS
VAN LEEN, ROBERT WILLEM, NETHERLANDS

(73) DSM N.V. NETHERLANDS

(30 (EP) EPO 86202285.2 1986/12/16
(EP) EPO 87201322.2 1987/07/13

(57) 38 Claims

Canada

OPIC CIPO

554,561

GIST-BROCADES N.V.

2431S

ABSTRACT OF THE DISCLOSURE

A cDNA encoding human interleukin-3, also designated herein hIL-3 or hmulti-CSF, has been disposed in expression systems and caused to produce hIL-3 substantially free of impurities normally accompanying this protein as it is produced inter alia by peripheral blood lymphocytes in nature. The resulting hIL-3 can be produced in practical amounts and is useful in a variety of therapeutic and diagnostic protocols.

MOLECULAR CLONING AND EXPRESSION OF HUMAN IL-3

Field of the Invention

The present invention relates to cDNA encoding human interleukin-3 (hIL-3) and its use, inter alia, in the cloning and expression in various organisms, including microorganisms, in particular yeasts, bacteria and fungi, tissue culture cells and transgenic animals and plants.

Background of the Invention

Hemopoiesis involves the active process of proliferation and differentation of pluripotent progenitor cells into all types of mature blood cells and some specialized tissue cells. Production of functional blood cells is regulated by specific proteins, the hemopoietic growth factors (HGFs). Some of the HGFs control maturation of a specific maturation lineage, whereas others stimulate proliferation and differentiation of progenitors along multiple pathways. Much of our knowledge of the hemopoietic differentiation process has been obtained from mouse studies *in vitro* and *in vivo*, using purified growth factors. The murine growth factor interleukin-3 (mIL-3), also termed Multi-CSF, mast cell growth factor, stem cell activating factor or several other designations, stimulates the proliferation of developmentally early, multipotent cells (CFU-S) as detected by the spleen colony assay, resulting in the production of progenitor cells along the erythroid, megacaryocyte, granulocyte/macrophage, osteoblast and several other lineages. Furthermore, mIL-3 has been implicated in replication of pluripotent stem cells, probably in synergism with other HGFs.

In recent years, several groups have succeeded in cloning mIL-3 cDNA. No results have been reported sofar of identifying homologous sequences in human DNA using mIL-3 DNA

as a probe. Presumably, the human gene has diverged extensively from the mIL-3 gene or has lost its function during primate evolution. However, human leukocytes were found to produce a HGF(s) which can replace mIL-3 in supporting the proliferation of murine CFU-S. Thus, the existence of a human HGF was postulated, which shares biological properties with mIL-3 and therefore could be the human homolog. Yang, Y-C, et al, Cell (1986) 47:3-10, dated 10 October discloses cDNA encoding a protein having IL-3 like activity from gibbon T-cells, and retrieval of a genomic DNA which encodes the human counterpart. The sequence of a cDNA encoding human IL-3 can be deduced from the human gene sequence published by Yang et al. However, said article does neither disclose nor teach a method for isolation of a cDNA encoding human IL-3, nor was the production of hIL-3 achieved. This invention describes for the first the isolation of a cDNA comprising the entire coding sequence for human IL-3.

Human IL-3 protein has never been prepared in purified form, nor have its characteristics, other than its activity in certain in vitro proliferation assays and deduced primary structure, been disclosed. The present invention permits the recovery of purified human IL-3, and identification of its characteristics through recombinant production from a cDNA clone.

Summary of the Invention

As stated above, the present invention for the time describes the isolation of a cDNA comprising the entire coding sequence for human IL-3. The low degree of homology between the DNA sequences coding for murine and human IL-3 does not permit the retrieval of a cDNA for hIL-3 by hybridization with the mIL-3 coding sequence. Unexpectedly, the hIL-3 cDNA clone could be isolated by exploiting the rather high degree of homology in the 3' noncoding part of the cDNA's. The availability of the cDNA clone permits the production of hIL-3 by a wide range of host organisms. Subsequent to large scale production the protein may be purified and used therapeutically.

The present invention permits production of recombinant human IL-3 protein in a wide range of host cells by transcription and translation from a cDNA sequence encoding the human IL-3 protein. The production of the protein is illustrated in several hosts, including E. coli, COS cells, C127 cells, B. subtilis and B. licheniformis, S. cerevisiae and K. lactis, hereinbelow. Production in other hosts using appropriate expression systems is also made possible by provision of the intronless cDNA. More generally, the availability of antihuman IL-3 antibodies which permit identification of colonies exhibiting successful production of the recombinant protein aids in production of human IL-3 from any recombinant system.

In one aspect, therefore, the invention is directed to a recombinant, intronless, DNA encoding human IL-3 protein.

In another aspect, it is directed to expression systems capable of effecting the expression of said DNA sequence encoding hIL-3 in an appropriate host.

In other aspects, the invention is directed to recombinant human IL-3 protein in glycosylated or unglycosylated form, to human IL-3 free of substances normally accompanying said protein, and to antibodies specifically reactive with these recombinant or purified proteins.

Brief Description of the Drawings

Figure 1 shows a comparison of DNA and protein sequences of human multi-CSF and mouse IL-3. The hmulti-CSF protein and DNA sequence (clone D11, top lines) were aligned with the mIL-3 DNA (11, 35) and protein sequence (30). Identical nucleotides are indicated by a vertical line, identical amino acids are shown in boxes. Black dots indicate a polyadenylation signal sequence and horizontal bars mark ATTTA repeat units.

Figure 2 shows the construction of plasmid pLB4 containing human IL-3 cDNA. E = EcoRI, Sm = SmaI, B = BamHI, S = SstI, K = KpnI.

Figure 3 shows the biological activity of COS/pLB4

CM on human bone marrow progenitors. The mean numbers of erythroid (BFU-E), granulocyte-macrophage (CFU-GM), granulocyte (CFU-G), eosinophil (CFU-Eo), macrophage (CFU-M) and mixed (CFU-MIX) colonies (±SD) are shown for duplicate cultures stimulated with graded volumes of COS/pLB4 CM.

Figure 4 shows induction of AML proliferation by COS/pLB4 CM as assessed in a colony culture assay (panel A) and in a DNA synthesis (^{3}H-TdR incorporation) assay (panel B).

Figure 5 shows a construction diagram of the E. coli expression vectors pGB/IL-301, GB/IL-302, pGB/IL-303, pGB/IL-304, pGB/IL-305 and pGB/IL-306. In this Figure X stands for XhoI, E for EcoRI, B for BamHI and A for AvaI site.

Figure 6 shows the sequence of the multicloning site in pTZ18R (Pharmacia) and its derivative pT1.

Figure 7 shows a schematic presentation of hmulti-CSF expression clones. For the eucaryote expression plasmids pLB4 and pLH1 only the hmulti-CSF cDNA insert is shown. Leader peptide (▨) and mature hmulti-CSF protein (■) coding regions are indicated in boxes. Bacterial expression clones of hmulti-CSF (derived from pLH1) contain the lacZ and multi-linker protein coding region (▩), the 5' terminal noncoding region of hmulti-CSF (▭) and the hmulti-CSF coding region. The arrow marks the ATG startcodon used in the particular vector.

Figure 8 shows the sequences of fusion regions of lacZ/hmulti-CSF DNA for various bacterial expression vectors. The sequence of clones is given from the start of the lacZ protein in either pUC8 or pTZ18R (lower case letters) and of hmulti-CSF DNA sequence up to the ClaI site at position 158. Mutations in the hmulti-CSF DNA sequence are underlined, resulting in: $trp^{13} \rightarrow arg^{13}$ (pGB/IL-302); $leu^{9} \rightarrow pro^{9}$ and $trp^{13} \rightarrow arg^{13}$ (pGB/IL-303); $met^{3} \rightarrow thr^{3}$ and a silent change (pGB/IL-304). The superscripts denote the amino acid residue number of the mature protein.

Figure 9 shows polyacrylamide gel-electrophoresis of bacterial hmulti-CSF produced from bacteria containing pGB/IL-301 and pGB/IL-302.

Figure 10 shows the titration of hmulti-CSF fusion

protein on AML blast cells.

Figure 11 shows a Western blot demonstrating the IL-3 specific reaction of rabbit antisera raised against the 21 kd protein isolated from a lysate of E. coli transformed with pGB/IL-301.

Figure 12 shows the effect of the antisera of Figure 11 on IL-3 activity.

Figure 13 shows a schematic representation of plasmid pGB/IL-307. The box (▨) indicates the human IL-3 coding sequence. The N-terminal amino acids of the fusion protein are depicted below the drawing.

Figure 14 shows a schematic representation of plasmid pGB/IL-308. The nucleotide sequence of the promoter region is depicted below the drawing.

Figure 15 shows the construction of plasmid pGB/IL-309. The first box (▭) indicates a part of the human IL-3 sequence, viz. the signal sequence plus 20 amino acids of the mature protein. The other box (▤) indicates part of the 3' noncoding region of the IL-3 cDNA sequence.

Figure 16 is a schematic representation of plasmid pGB/IL-310.

Figure 17 shows the nucleotide sequence of plasmid pBHA1.

Figure 18 shows the construction of the plasmids pGB/IL-311 and pGB/IL-312. The box (▨) indicates the precursor human IL-3 coding region.

Figure 19 shows the construction of the plasmid pGB/IL-313. The sequence at the 5' side of the IL-3 sequence is depicted below the drawings.

Figure 20 shows a schematic representation of plasmid pGB/IL-317.

Figure 21 shows a schematic representation of plasmid pGB/IL-316.

Figure 22 shows the nucleotide sequence of plasmid pGB/IL-316 between the unique SacII site in the lactase promoter and the HindIII site behind the terminator (residues 4457 to 7204).

Figure 23 shows the nucleotide sequence of plasmid

pGB/IL-318 between the unique SacII site in the lacatse promoter and the HindIII site behind the terminator (rcsidues 4457 to 7190).

Figure 24 shows the nucleotide sequence of the EF-1α promoter, SalI-BglII-XhoI linker and actin terminator as present on plasmid pGB/TEFact.

Detailed Description of the Invention

A. Definitions

As used herein, "human IL-3", "hIL-3, "human multi-CSF", and "hmulti-CSF" are used interchangeably, and designate a protein preparation which exhibits the following activities:

1. The protein stimulates colony formation by human hemopoietic progenitor cells wherein the colonies formed include erythroids, granulocytes, granulocyte macrophages, and mixed.

2. The protein stimulates DNA synthesis by human acute myelogenous leukemia (AML) blasts, as evidenced, for example, by labeled thymidine uptake.

To fit the definition of hmulti-CSF, the activity in the foregoing assay must not be substantially inhibited by antibodies raised in response to, and immunospecific for, GM-CSF, unless these antibodies also inhibit these activities by the illustrative hmulti-CSF below.

One illustrative form of hmulti-CSF is shown in Figure 1 as a 133 amino acid mature protein, having a 19 amino acid signal sequence. The amino acid sequence of Figure 1 is identical with that disclosed by Yang, Y-C., et al., Cell (1986) 47:3-10 (supra) except at position 8 of the mature protein wherein the Ser of the Yang protein is replaced by Pro herein. As shown herein, this amino acid sequence is effective in its nonglycosylated form. However, it contains two glycosylation sites, and the glycosylated form is also included within the scope of the invention. It is also recognized that the protein may exist in acid addition salt

form, basic salt form, or may be neutral, depending upon the pH of its surroundings. Derivatization by phosphorylation, acetylation, and so forth, to the extent that activity is not destroyed, also results in a protein included within the scope of the invention.

It is also recognized that the entire sequence may not be necessary for activity. Parts of the amino acid sequence may be deleted or replaced, while retaining biological activity. As illustrated herein, the alanine at position 1 may be deleted, as may as many as the first fourteen amino acid residues if replaced by a sequence of residues of a fused peptide sequence. In addition, it is believed that the murine form of the protein requires only the first 79 residues for activity; this corresponds approximately to the first 83 residues of the human counterpart. Accordingly, fragments which comprise only the first 83 amino acid residues of the protein, and the N-terminal replaced forms thereof are also included within the scope of the invention. Furthermore, it should be considered that the N-terminus of mature hIL-3 is formed by the residues ala-pro-met etc. (see Figure 1). It is known that the protein, when secreted by a yeast host, may in some instances be shortened by two amino acids (ala-pro), due to the interaction with a dipeptidyl-aminopeptidase (72). The hIL-3 without the N-terminal alanine and proline still retains its biological activity. Yeast strains carrying a null mutation of the X-prolyl dipeptidyl-aminopeptidase gene will produce complete hIL-3 (amino acids 1-133). Accordingly, included in the multi-CSFs of the invention are those which contain and those which do not contain the N-terminal alanine and proline, produced by X-prolyl dipeptidylaminopeptidase mutants and wild type hosts, respectively.

When produced as a mature protein in a procaryotic host, the coding sequence for the mature protein will be prefaced by an ATG start codon. The resulting N-terminal methionine may then be removed, or partially removed, by processing within the bacterial host, depending on the nature of the subsequent amino acid sequence. Again, both forms of

hIL-3 are biologically active. Therefore, included in the hmulti-CSFs of the invention are those which contain and those which do not contain the N-terminal methionine.

From the above it is clear that amino acid changes may be introduced into the human IL-3 protein, without affecting its biological function. It is recognized that minor changes in amino acid sequences by chemical modification of the encoded residue, substitution of a different residue, or deletion or addition of one or more, but preferably only one, residue results in proteins which retain activity. Accordingly, these nondestructive mutations are also included within the invention, in particular, the naturally occurring allelic variations and other mutations which are nonlethal to the activity.

On the other hand it should be considered that amino acid changes in the human IL-3 protein may be beneficial to the therapeutic use of the protein. As recognized herein, the mature protein has four conserved domains at residues 15-36, 54-61, 74-91, and 107-118. Proteins containing single and multiple amino acid changes in the nonconserved regions, 1-14 (which are, in any event, replacable by the sequences of host derived fusion proteins), 37-53, 62-73, 92-106, and 119-133 are possible. However, it appears that the cysteine residues at positions 16 and 84 may be necessary for disulfide bridge formation as they are conserved between species. Changes in the conserved domains mentioned above may influence biological properties of the protein, such as receptor binding and signal transduction. It is envisaged that hIL-3 having altered properties are of therapeutic use. Such derivatives of hIL-3, which may be made by known protein engineering techniques, are to be understood within the scope of the present invention.

The protein preparation may contain the hmulti-CSF peptides in monomeric or aggregated form, provided the aggregates retain activity as above-defined.

As used herein, "expression system" refers to a DNA sequence which contains both a coding sequence whose expression is desired and appropriate control sequences in

operable linkage with it which permits its expression when the control sequences are compatible with the host into which the exprcssion system is placed. As is generally understood, "control sequences" refers to DNA segments which are required for or regulate the expression of the coding sequence with which they are operably linked.

Control sequences for all hosts include promoters, which may or may not be controllable by regulation of their environment. Typical promoters suitable for procaryotes include, for example, the trp promoter (inducible by tryptophan deprivation), the lac promoter (inducible with the galactose analog IPTG), the beta-lactamase promoter, and the phage-derived P_L promoter (inducible by temperature variation). Additionally, especially for expression in Bacillus, useful promoters include those for alpha-amylase, protease, Spo2 and synthetic promoter sequences. Suitable promoters for expression in yeast include the 3-phospho-glycerate kinase promoter and those for other glycolytic enzymes, as well as promoter regions for alcohol dehydrogenase and yeast phosphatase. Also useful are the transcription elongation factor (TEF) and lactase promoters. Mammalian expression generally employs promoters derived from viruses such as the adenovirus promoters and the SV40 promoter systems, but they also include regulatable promoters such as the metallothionein promoter, which is controlled by heavy metals or glucocorticoid concentration. There are also now available viral-based insect cell expression systems, as well as expression systems based on plant cell promoters such as the nopaline synthetase promoters.

In addition to the promoter DNA sequence, which is necessary for the transcription of the gene by RNA polymerase, a variety of control sequences, including those regulating termination (for example, resulting in polyadenylation sequences in eucaryotic systems) are also useful in controlling expression. Some systems also contain enhancer elements which are desirable but not necessarily necessary in effecting expression.

Translation controls include a ribosome binding site

(RBS) in procaryotic systems, whereas in eucaryotic systems translation may be controlled by the nucleotide sequence around the AUG codon.

As implied above, recombinant protein production can be effected in a wide variety of hosts, including bacteria (predominantly E. coli, Bacillus, and Streptomyces), in yeast and fungi (such as Saccharomyces, Kluyveromyces, and Aspergillus), and in mammalian and other cell cultures such as COS cells, C127 cells, Chinese hamster ovary cells, Spodoptera frugiperda (Sf9) cells, and so forth. The protein may be produced as an intracellular mature or fusion protein, or may be secreted when the DNA encoding an appropriate compatible signal is included in the gene.

The present invention for the first time enables large scale production of recombinant human IL-3, so that this protein - in purified form - can now be used as a therapeutic agent. The methods described herein provide means for producing glycosylated as well as unglycosylated forms of the protein, which can be purified to substantially pure human IL-3. "Purified" human IL-3 refers to human IL-3 as defined above which is free of other proteins which normally accompany it.

B. Retrieval of cDNA Encoding Human IL-3

Human IL-3 was isolated according to the following strategy:

1. A procedure was developed which allowed for reproducible production of hemopoietic growth factors (HGFs) by human leucocytes.

2. mRNA was prepared from such producing cells and transcribed into double-stranded cDNA.

3. The cDNA was screened with a complete mIL-3 cDNA which contained both the coding and untranslated 3' downstream portions to obtain DII.

4. The hybridyzing cDNA clone DII was inserted into an expression vector pLO to obtain pLB4 which was expressed in COS cells to confirm the presence of the sequence encoding human IL-3. Conditioned media from these cells showed the

biological activity expected of hIL-3.

The human cDNA was retrievable using this procedure because despite considerable lack of homology with the murine coding sequence, a surprising degree of homology was present in the 3' untranslated region. Applicants are unaware of any prior disclosure of the use of a 3' untranslated sequence homology to retrieve an alternate species gene.

In more detail, conditioned medium of lymphocytes cultured in the presence of 12-0-tetradecanoylphorbol-13 acetate (TPA) and concanavalin A (Con A) is a suitable source for human HGFs as determined by assay of the medium using stimulation of mouse CFU-S in suspension cultures, proliferation of mIL-3 dependent DA-1 cells, human hemopoietic progenitor assays by colony formation in vitro, and in vitro stimulation of acute leukemia blasts. A cDNA library from human lymphocytes was constructed in lambda gt-10 phage (20) and screened using the HindIII-XbaI fragment of mIL-3 cDNA, for the occurrence of mIL-3 related sequences. No hybridizing clones were identified.

However, when complete murine IL-3 cDNA was used as probe, four clones were identified. Restriction enzyme analysis of the largest clone (D11) indicated a 910 bp insert containing an internal EcoRI site (at position 411, Figure 1).

(It was investigated whether this EcoRI site had arisen by ligation of two independent cDNA fragments or was a naturally occurring site. Southern analysis of restriction enzyme digested human DNA using labeled 5' and 3' EcoRI fragments of clone D11 as probe, revealed identical DNA fragments following digestion with HindIII (15 kb) and BamHI (4.6 kb). Furthermore, the DNA sequence around the EcoRI site does not correspond to linker sequence (pCCGAATTCGG) used for inserting cDNA into phage DNA, indicating that these EcoRI fragments are derived from a single mRNA.)

From hybridization and sequencing experiments it was concluded that the small clones (II, IV and VI) are identical to the 3' nucleotide sequence of clone D11 and derived from the same mRNA species.

Computer assisted alignment (Figure 1) of the D11

cDNA and the mIL-3 cDNA revealed sequence homology in the 5' terminal 100 bp, between nucleotides 236-269 and between nucleotides 598-803 in the 3' terminal region (68%, 71% and 73% homology, respectively). In particular, the region between nucleotides 706 and 763 is highly conserved (93% homology) and contains repetitive AT-rich sequences. The low homology in the 5' terminal 600bp of the human cDNA (52%) precludes detection by hybridization with the HindIII-XbaI fragment of mIL-3.

Analysis of the human cDNA clone for an encoded protein shows an open reading frame up to the termination codon TGA at position 495-497 (Figure 1). The first ATG triplet is probably the actual initiation codon of the encoded polypeptide. The putative encoded protein consists of a hydrophobic leader peptide of 19 amino acids, which is probably cleaved between the glycine and alanine residues (22, 23).

The alignment of the predicted amino acid residues of the human and mouse IL-3 (Figure 1) reveals a homology of 50% for the leader peptide (residues -26 to +1) and 28% for the mature protein (residues 1 to 133). Within the leader peptide, there are two conserved regions of four amino acids (residues -13 to -10 and -3 to +1), of which the second one encloses the processing site. The mature protein is 133 amino acids long and has a molecular weight of 15 kd. The mature protein has four conserved domains (residues 15-36, 54-61, 74-91 and 107-118) and contains two potential glycosylation sites (residues 15-17 and 70-72). Both cysteine residues present in the human protein (positions 16 and 84) are conserved and may play an essential role in protein folding by disulfide bridge formation.

In order to verify that this human cDNA encodes a functional protein that resembles mIL-3, the D11 cDNA was inserted in an eucaryotic expression vector (pLO, containing a SV40 transcription unit) to obtain the expression vector pLB4 and transfected to COS 1 cells. The COS/pLB4 conditioned medium (CM) was tested for (1) its capacity to stimulate colony formation by human bone marrow cells, and (2) to stimulate human acute myelogenous leukemia (AML) blasts.

<u>In vitro</u> colony growth of human hemopoietic

progenitors depleted of myelomonocytic (Vim-2 positive) and T-lymphocytic (T-3 positive) accessory cells, was efficiently stimulated by COS/pLB4 CM. The data demonstrate stimulation of progenitors of several hemopoietic differentiation lineages and of a subpopulation of BFU-E by COS/pLB4 CM.

In a separate experiment, bone marrow was enriched for progenitor cells by density centrifugation, E-rosette sedimentation to remove T-lymphocytes and adherence to remove mononuclear phagocytes and cultured in enriched medium containing fetal calf serum. Under these conditions, the majority of the colonies obtained upon stimulation with COS/pLB4 CM contained two or more hemopoietic differentiation lineages: all contained macrophages, approximately half immature blasts and/or immature erythroid cells and/or neutrophilic granulocytes and a minority, in addition, basophilic or eosinophilic granulocytes. These results demonstrate the multilineage stimulatory properties of the protein encoded by the human cDNA clone D11 and its action on developmentally early, multipotent hemopoietic cells.

With respect to AML stimulation, AML blasts of five patients were stimulated with the COS/pLB4 CM and assayed for a response by measuring ^{3}H-TdR incorporation and colony formation. Three of the five leukemia cell samples responded to the COS/pLB4 CM in both assays; characteristic dose-response relationships for colony formation and DNA synthesis of AML blasts of different patients were obtained. The responses to GM-CSF demonstrated further phenotypic differences among the leukemias responding to the COS/pLB4 CM.

These data demonstrate that the D11 cDNA clone contains the complete genetic information for a biologically active protein which is exported into the culture medium in the transformed COS cells. Despite the apparent lack of homology with respect to the protein sequence between the human protein and mIL-3 (only 30%), the proteins are comparable with respect to their biological function. Both proteins exert their effect on developmentally early hemopoietic progenitors of various lineages. The low homology

at the amino acid level is also reflected by a low homology in the coding nucleotide sequence. However, very unexpectedly, a rather high degree of homology -- sufficient for retrieval of the human cDNA clone -- occurred in the 3' untranslated region.

Southern analysis of human DNA revealed a single hybridizing gene indicating that this cDNA does not belong to a family of closely related genes.

From the foregoing results we conclude that the human cDNA insert in D11 encodes the human homolog of mIL-3. We decided to use the operational term hmulti-CSF for the protein encoded by the cDNA clone D11 in view of its major biological effect and assay.

The identification of hmulti-CSF cDNA clones by virtue of hybridization with the 3' terminal region of the mIL-3 cDNA was unexpected. Whereas homologous DNA sequences are in general predominantly found in the coding region, the hmulti-CSF sequence has extensively diverged (45% homology) in this part of the gene. Analysis of the highly conserved domain in the 3' terminal non-coding region reveals the occurance of 5 ATTTA repeat units which are all preserved in the mIL-3 cDNA (Figure 1).

hMulti-CSF and mIL-3 display considerably less protein homology than other murine and human growth factors or lymphokines such as GM-CSF (25), interleukin-2 (25), interleukin-1 (26) and interferons (27-29). The biological activity of the mature mIL-3 appears to be contained in the first 79 amino acids, including an absolute requirement for the cysteine residue at position 17 (30). This cysteine residue is conserved in hmulti-CSF (Fig. 1, pos. 16) and may play an essential role in protein folding. The occurrence of a potential glycosylation site around this cysteine residue may interfere with disulfide bridge formation.

C. <u>Production and Formulation of hmulti-CSF</u>

Applicants have provided a representative variety of expression systems capable of producing human IL-3 protein in a variety of forms -- as fusion proteins, as mature intra-

cellular proteins, and as secreted proteins. Applicants are unware of availability anywhere in the art of recombinant forms of human IL-3, or, indeed, of any human IL-3 in a preparation which is free of proteins normally accompanying this desired protein. Accordingly, the invention herein provides, for the first time, the human IL-3 protein in a manner which is capable of adaptation to therapeutic and diagnostic uses.

The human IL-3 can be produced as a fusion protein with sequences heterologous to the human IL-3 amino acid sequence. By "heterologous" is meant a sequence which is not found in human IL-3 itself, but is an unrelated sequence. This heterologous sequence may be derived from a bacterial protein, a yeast protein, a mammalian protein, or any of variety of miscellaneous fortuitously encoded sequences such as, for example, those encoded by polylinkers. It is clear from the results hereinbelow that at least the first 14 amino acids of the N-terminus of the human IL-3 sequence can be replaced by a heterologous sequence, at least if the fusion protein is further extended past the N-terminus.

The protein can also be obtained as a mature intracellular protein by constructs in which the ATG start codon is placed immediately upstream of the desired N-terminus. These intracellular proteins, whether mature or fusion proteins, can be recovered by lysing the cells and purifying the human IL-3 using standard protein purification techniques.

Protein purification is simplified if the human IL-3 is secreted into the medium. When produced in mammalian cells with which the native signal sequence is compatible, this native signal sequence can be used to effect secretion into the medium. In bacterial or yeast systems, signal sequences compatible with these hosts, such as the penicillinase or alpha-amylase sequence in bacteria or the alpha-factor signal sequence in yeast can be used.

When produced recombinantly, the human IL-3 is free of proteins normally accompanying it, and can be purified from the proteins and other materials indigenous to the recombinant

host using, for example, chromatographic methods, gel filtration, ammonium sulfate precipitation, and so forth.

As described hereinbelow, the protein is useful for therapeutic and diagnostic purposes. For therapeutic uses, the protein may be formulated in ways standard for pharmaceutical compositions which are used for the administration of proteins. Suitable excipients include, for example, physiological saline, Ringer's solution, and so forth. Alternate formulations, including solid formulations (e.g. lyophilized), can also be employed.

D. Preparation of Antibodies

The availability of recombinant IL-3 protein or parts thereof will permit production of antibodies directed against the protein or parts thereof, as demonstrated hereinbelow. Such antibodies are useful, inter alia, for in vitro detection of colonies producing hIL-3, for therapeutical use, and for the purification of both natural and recombinant hIL-3.

Statement of Utility

The nucleotide sequence of the whole or parts of the cDNA of human IL-3, or closely-related DNA sequences will advantageously enable the detection of genetic abnormalities, including genomic rearrangements, restriction fragment-length polymorphisms, mutations and altered gene expression with the use of such techniques as the analysis of chromosomal DNA using restriction enzymes, DNA and RNA blotting as well as hybridization techniques (Maniatis et al. 1982) and two-dimensional gel electrophoresis (Fisher and Lerman, 1983).

The recombinant hmulti-CSF as provided by the present invention will facilitate a detailed analysis of its role in human hemopoiesis, in particular the possible synergism of hmulti-CSF and various other HGFs. Furthermore, hmulti-CSF is of considerable interest because of its applicability for in vitro diagnosis of human diseases in

which hemopoietic progenitor cells are involved, which include the leukemia, as well as potential therapeutic applications aimed at expansion of hemopoiesis in vivo. The effect of hmulti-CSF on various hemopoietic malignancies with respect to terminal differentiation of the leukemic cells also needs to be explored. In addition hMulti-CSF may be required for establishing a proliferative state of human stem cells in gene therapy protocols, since stimulation with mIL-3 was shown to be required for succesful infection of mouse stem cells with recombinant, replication defective retroviruses.

IL-3 protein can also advantageously be used for the detection of early hemopoietic precursor cells in standardised in vitro cultures (Wagemaker and Visser, 1980; Metcalf et al. 1982; Merchav and Wagemaker, 1984, Metcalf, 1986).

IL-3 protein and variants can further be used for the multiplication of hemopoietic stem cells in vitro, possibly in conjunction with other growth factors, for bone marrow transplantation and the genetic manipulation of stem cells (Lowenberg and Dicke, 1977; Wagemaker and Petem, 1978; Lemischka et al, 1986).

The IL-3 protein can be used for the determination of the response pattern of malignant hemopoietic cells in in vitro tests (Touw and Lowenberg, 1985; Griffin et al, 1986; Griffin and Lowenberg, 1986).

The IL-3 protein can further be used for the detection of remaining leukemic cells by in vitro methods (Touw and Lowenberg, 1986; Griffin et al, 1986; Griffin and Lowenberg, 1986).

Furthermore, the IL-3 protein can be used in vivo for the treatment and prevention of malignant and non-malignant disorders, either by itself or in combination, in which an obtained specific response by the hemopoietic system can result in a clinical benefit.

These applications include:

- cytopenias and/or immunosuppression due to infections such as AIDS
- cytopenias due to chemotherapy and/or irradiation
- bone disorders such as bone fractures and osteoporosis

- immunodeficienties due to general anaesthetic procedures
- recovery following bone marrow transplantation
- adjunct to vaccinations and adjunctive therapy of infections.

The cloned human IL-3 DNA sequence or closely-related DNA can be used for gene therapy in genetic deviations from the normal IL-3 gene.

To facilitate the above-described analysis, a large quantity of human IL-3 is required. The easiest way to obtain sufficient amounts of the protein is the production with microorganisms, in particular yeasts, bacteria and fungi, e.g. Saccharomyces, Kluyveromyces, Aspergillus, Streptomyces, Bacillus and E. coli species. Production in mammalian and other eucaryotic systems, such as C127 cells, Spodoptera cells and transgenic animals and plants, is also possible for skilled persons following the teaching of the present invention. These possibilities are all included within the scope of this invention.

As an illustration how to obtain living cells that produce the human IL-3 protein by expression of the hIL-3 cDNA, a number of plasmids were constructed and transferred to E. coli, B. subtilis, B. licheniformis, S. cerevisiae, K. lactis and C127 cells. Using these host strains the production of recombinant human IL-3 was achieved. The products were tested for their capacity to stimulate human AML blasts as described above for the COS/pLB4 conditioned medium. From these experiments it appeared that the proteins made were biologically active.

The following examples are intended to illustrate but not to limit the invention.

Example 1

Retrieval of cDNA Encoding Human multi-CSF (hmulti-CSF)

Human leukocytes stimulated with TPA (5 ng/ml) and ConA (10 ug/ml) produced considerable amounts of HGFs as measured by the murine stem cell proliferation assay and various other colony assays. Cells were harvested 24 hrs after stimulation, because mRNA production is often transient following stimulation with phorbol esters and lectins. Already after 24 hrs, HGFs were easily detectable in the CM.

mRNA Preparation

Cells were harvested, washed with PBS and homogenized in guanidinium isothiocyanate solution (36). RNA was pelleted through a cesium chloride cushion. Oligo(dT)-cellulose chromatography was used for selection of mRNAs (36).

cDNA Synthesis

cDNA was synthesized essentially according to Gubler and Hoffman (37), using oligo(dT) as primer and AMV reverse transcriptase. Second strand was synthesized with RNaseH and *E. coli* DNA polymerase I. Gaps were closed with T4-DNA ligase and ends were flushed by T4-DNA polymerase. To protect internal EcoRI restriction sites, the cDNA was methylated with EcoRI methylase. Subsequently, the cDNA was ligated to phosphorylated EcoRI linkers with T4-DNA ligase. After digestion with EcoRI, excess linkers were removed by Sepharose CL-4B chromatography. The material recovered in the void volume of the column was larger than 250bp and was used for construction of the libraries.

Construction of the Phage cDNA Library.

The cDNA was ligated to lambda gt10 phage arms (20) and packaged with commercial packaging extracts (Gigapack, Vector Cloning Systems). The recombinant phages were propagated in *E. coli* C600 hfl.

Screening of the Phage Library.

Of each plate containing 1-5000 plaques, two nitrocellulose filter replicas were made according to standard procedures. Filters were then hybridized with radiolabeled mIL-3 probe from the HindIII-XbaI fragment of mIL-3 cDNA or with the complete mIL-3 cDNA clone radiolabeled with random primers. The mIL-3 cDNA clone (pL101) was isolated from a WEHI-3B cDNA library. WEHI-3B mRNA was isolated using the guanidinium isothiocyanate CsCl method, size fractionated on sucrose gradient and injected into Xenopus laevis oocytes. RNA fractions inducing the oocytes to produce a factor capable of supporting murine stem cell proliferation, were used for synthesis of cDNA as described above, cDNA was tailed with dC residues and inserted in the PstI site of pUC9. mIL-3 clones were identified using synthetic oligonucleotides (from published mIL-3 sequence, 11). Insert of pL101 was purified on polyacrylamide gel and used for screening of the human cDNA library. Probe DNA was labeled using the random primer method (38). Potential positive plaques were rescreened and plaque purified. In this way four clones were identified, including phage D11.

Sequencing of cDNA Clones.

Recombinant phages were grown at large scale and purified, cDNA inserts were removed from the phage arms by digestion with EcoRI and purified on polyacrylamide gel. The purified fragments were ligated into M13mp18 and pTZ18R DNA digested with EcoRI and used for transformation of E. coli JM109. Single strand DNA was prepared and sequenced according to established procedures (39). Sequence data were analyzed using various computer programs (40-43).

The sequence obtained for the insert in phage D11 is shown in Figure 1. This 910 bp sequence contains the entire coding region for hmulti-CSF and its signal sequence, and exhibits high homology to the murine clone pL101 in the 3' untranslated region. The homology upstream in the coding sequence is relatively more limited. As described above, the protein has a putative 19 amino acid signal sequence followed

by a 133 amino acid mature protein containing two glycosylation sites (15-17 and 70-72) and two cysteine residues at 16 and 84.

The deduced amino acid sequence is the same as that encoded by the genomic DNA disclosed by Yang, Y-C, et al. (supra), except for one amino acid -- that at position 8 of the putative mature protein; the Yang DNA encodes Ser, the cDNA herein encodes Pro.

The intronless sequence obtained in the phage D11 can be used for procaryotic expression, as well as for expression in eucaryotic systems, as illustrated below.

Example 2

Expression in Mammalian Cells

A. Construction of the eucaryote expression vector pLB4

Phage D11 (containing the longest cDNA insert) was digested with Hind III and BglII and subcloned in plasmid pT1 (a derivative of pTZ18R, containing some additional restriction sites in the multilinker, see Example 3A). Clones containing the phage fragment containing the cDNA insert were identified by restriction analysis. The cDNA insert was removed from this plasmid by partial digestion with EcoRI and purified by polyacrylamide gel electrophoresis. The appropriate fragment was inserted in a eucaryote expression vector (pLO) in an SV40 transcription unit.

pLO comprises: EcoRI (filled in) - PstI of pBR322 (1-755), PstI-AvaI of pBR329 (756-1849), AvaI-PvuII adapter (1850-1868), PvuII-HindIII (filled in) of SV40 (promoter) (1869-2211), PvuII-BamHI adapter containing the unique EcoRI site (2211-2251), MboI "splice fragment" of SV40 (2252-2861), BclI-BamHI (filled in) "poly A fragment" of SV40 (2862-3098), PvuII-HindIII promoter fragment of SV40 (3099-3440), HindIII-BamHI Eco gpt gene (3441-4501), MboI "splice fragment" of SV40 (4502-5111) and the BclI-BamHI (filled in) "poly A fragment" of SV40 (5112-5348).

The Eco gpt transcription unit is of no importance

in transient expression of proteins in COS 1 cells. The resultant expression plasmid for hmulti-CSF was termed pLB4 and was purified on CsCl. This plasmid in E. coli was deposited with the Centraal Bureau of Schimmelcultures (CBS), Baarn, the Netherlands, under the provisions of the Budapest Treaty on December 12, 1986 under CBS 568.86. The construct is shown in Figure 2.

B. Expression of hmulti-CSF in COS 1 Cells and Bioassays.

pLB4 DNA was transfected to COS 1 cells using the calcium phosphate coprecipitation method (45). Cells were cultured for 48-72 hours in alpha medium containing 10% fetal calf serum. The culture medium was recovered, filtered and used in assays for establishing its biologic activity. Human bone marrow progenitor colony assays and acute myeloid blasts colony and proliferation assays were performed as follows. Bone marrow was obtained from hematologically normal adult volunteers by posterior iliac crest puncture following informed consent. The mononucleated cells were separated by density gradient centrifugation on a Ficoll gradient (Nijegaard and Co., Oslo, Norway), washed and resuspended in Hanks balanced salt solution (HBSS). Myeloid cells and T-lymphocytes were then removed. For this purpose, marrow cells were lysed following incubation with monoclonal antibodies OKT-3 (CD3; Ortho, Ravitan, N.Y.) and Vim 2 (myelo-monocytic cells, 46) at saturating concentrations in the presence of rabbit complement (40%; 30 minutes, 25°C) according to established procedures (47). The cells were washed two times in HBSS, resuspended in Iscove's modified Dulbecco's medium (IMDM) and cultured in the presence of autologous plasma according to Fauser and Messner (16), as described before (48), at a concentration of 1.5-3 x 10^4/ml. Erythropoietin 1 U/ml (sheep, step III, Connaught, Willowdale, Canada) and COS/pLB4 CM were added as growth stimulating activities. Results of standard cultures with phytohaemagglutinin stimulated leukocytes CM (PH-LCM) in direct comparison with COS/pLB4 CM are also given. Sixty percent of the colonies were plucked and identified by microscopical analysis. The CM from

COS cells transfected with the vector without insert (pLO) failed to stimulate colony formation by itself.

The results are shown in Figure 3. As shown in the figure, the mean numbers of erythroid (BFU-E), granulocyte-macrophage (CFU-GM), granulocyte (CFU-G), eosinophil (CFU-Eo), macrophage (CFU-M) and mixed (CFU-MIX) colonies (±SD) are shown of duplicated cultures stimulated with graded volumes of COS/pLB4 CM.

Induction of AML Proliferation (see Figure 4)

AML blasts were purified using a bovine albumin (BSA) density gradient. Residual T-lymphocytes were removed from the AML samples by E rosette sedimentation (17, 49, 50). AML (patient 1) colony formation was determined not only in the established PHA leukocyte feeder (PHA l.f) system, but also in a modified version of the technique in which the leukocytes were replaced by COS/pLB4 CM, permitting assessment of its colony-stimulating activity (17, 18, 49, 50) as shown in Figure 4A. All experiments were performed in triplicate. DNA synthesis of AML blasts (patient 2) was assayed by thymidine uptake as described (51) with results shown in Figure 4B. Both assays showed a dose dependent relationship to COS/pLB4 CM added. Addition of control COS medium did not affect AML proliferation in either assay.

C. Construction of eucaryotic expression vector pLB4/BPV

In order to establish stable cell lines expressing human IL-3, C127 cells (ATCC CRL 1616) were transfected with a derivative of pLB4. This derivative was constructed by insertion of the entire BPV-1 genome (69) into pLB4 by the following strategy. The BPV-1 BamHI fragment was excised from the vector pdBPV-MMTneo(342-12) (70). The BamHI sticky ends were filled in using Klenow polymerase. Then the vector pLB4 was cleaved at the unique EcoRV site within the Eco gpt gene. Subsequently, the blunt-ended BPV-1 fragment was cloned into the EcoRV cleaved pLB4, resulting in the vector pLB4/BPV which is able to replicate in C127 cells. pLB4/BPV was transfected

to C127 cells using the calcium phosphate precipitation method (45). The transfected cells were cultured for 16 days, after which foci were picked from the culture dishes. Several independent cell lines were established. The pLB4/BPV vector appears to be stably maintained within the cells, as judged by Southern blotting of Hirt extracts (71) of several cell lines. Conditioned culture medium was tested for IL-3 activity using the AML proliferation assay. The stable cell lines produce active human IL-3.

Example 3

Construction of E. coli Expression Vectors

A. Construction of pGB/IL-301 (see Figures 5, 6, 7 and 8)

For construction of E. coli expression vectors, the following modifications were performed according to standard procedures (36).

1. The 3'-terminal noncoding sequences between the AvaI site (position 541) and the XhoI site (position 856) in pLB4 were deleted by fusion of the DNA fragments following filling of the sticky ends with Klenow enzyme (Figure 5).

2. For introduction of the hmulti-CSF insert into a bacterial expression vector, the following steps were performed. The pLH1 vector was digested with AvaII and the recessed ends filled with Klenow polymerase. Following ligation of a BglII linker (CAGATCTG), the DNA was digested with BglII and BamHI. The BglII-BamHI hmulti-CSF fragment was purified on polyacrylamide gel and subcloned in the BglII site of pT1, a derivate of pTZ18R (Pharmacia) modified in the multiple cloning site (see Figure 6). Two clones were obtained, which had the insert in the opposite orientation with respect to the lacZ promoter (see Figure 5). Inserts of these two clones were isolated on polyacrylamide gel following digestion with BglII and EcoRV and subcloned in pT1 digested with BglII and HindII. The junction of the BglII linker and the hmulti-CSF DNA was verified by sequence analysis and showed a fusion of the linker to the AvaII site located at

nt 1 of the cDNA clone (this AvaII site had arisen by ligation of the EcoRI linker to the cDNA molecule). Since this construct (pGB/IL-300) was not in phase with the lacZ protein, the Bg1II-EcoRV insert was subcloned into BamHI and HindII digested pUC8 (52). The resulting construct (pGB/IL-301, see Figures 5, 7 and 8) was tested for production of a lacZ/hmulti-CSF fusion protein.

B. Construction of pGB/IL-302, pGB/IL-303, pGB/IL-304 and pGB/IL-305 (Figures 5, 7 and 8)

Several base changes were introduced into the coding sequence for the N-terminal part of the fusion proteins by introduction of synthetic oligo nucleotides into pGB/IL-300. The new expression vectors, called pGB/IL-302, pGB/IL-303 and pGB/IL-3024 were constructed as follows: the HindII-HindIII fragment of pGB/IL-300 was isolated on agarose gel and ligated to a synthetic oligonucleotides comprising the nucleotides 99-137 of hmulti-CSF and a 5' terminal SalI recognition sequence and inserted into pTZ18R digested with SalI and HindIII. The sequence of several clones was established. Indeed, several base changes were observed, resulting in modifications of the hmulti-CSF protein. Inserts of several clones were transferred to pUC8 for expression of the lacZ fusion protein (pGB/IL-302, pGB/IL-303). Clone pGB/IL-304 was made in fase with lacZ by ligation of the SalI site following filling of recessed ends with Klenow. Construction was verified by PvuI digestion. Several clones lacked a synthetic oligonucleotide and were found to be fused in frame to the lacZ protein. One example of these clones was called pGB/IL-305.

C. Construction of pGB/IL-306 (see Figures 5, 7 and 8)

An expression vector coding for a protein lacking the lacZ N-terminal amino acids was made from pGB/IL-300 by deletion looping as described in (53). The synthetic oligonucleotide comprised 22 nucleotides upstream of the pTZ lacZ gene including the ATG start codon and the first 24 nucleotides coding for mature IL-3. This plasmid was called pGB/IL-306 (Figures 5, 7 and 8).

E. coli strains containing the plasmids pGB/IL-300, pGB/IL-301 and pGB/IL-302 were deposited with CBS on July 13, 1987 under CBS 377.87, CBS 379.87 and CBS 378.87, respectively.

Figure 8 shows the sequence of fusion regions for the various plasmids constructed. The sequence of the clones is given from the start of the lacZ protein coding region in either pUC8 or pTZ18R (lower case letters) and of the hmulti-CSF coding region (upper case letters) up to the ClaI site at position 158. Mutations in the hmulti-CSF DNA sequence are underlined, resulting in $trp^{13} \rightarrow arg^{13}$ (pGB/IL-302); $leu^{9} \rightarrow pro^{9}$ and $trp^{13} \rightarrow arg^{13}$ (pGB/IL-303); $met^{3} \rightarrow thr^{3}$ and a silent change (pGB/IL-304).

In the priority application, other designations were used for these plasmids as follows:

pGB/IL-300 = pT-hIL3;
pGB/IL-301 = pUC/hmulti;
pGB/IL-302 = pUC/hmultiΔ1A;
pGB/IL-303 = pUC/hmultiΔ1B;
pGB/IL-304 = pUC/hmultiΔ1C;
pGB/IL-305 = pUC/hmultiΔ2;
pGB/IL-306 = pTZ/hmulti.

D. Expression of lacZ/hmulti-CSF Fusion Proteins and Mature hmulti-CSF in E. coli

E. coli strains (JM 109) carrying various expression vectors were grown in LB medium containing 50 µg/ml of ampicillin at 37°C until an optical density of 0.5 at 550 nm was reached. Subsequently IPTG (isopropyl beta-D-thiogalactoside, Pharmacia) was added to the culture to a final concentration of 1 mM and incubation was continued for 3-4 hours.

Plasmids pGB/IL-306 and pGB/IL-302 were also transformed to E. coli DH1 (wild type lacZ operon). Those strains were grown in LB medium or 2 x TY medium containing 50 µg/ml of ampicillin at 37°C for 16 hours.

Bacteria were collected by centrifugation and sonicated in buffer containing 0.1 M Tris/HCl, pH 8.0; 5 mM EDTA 0.2% *Nonidet P40 (NP-40) and 1 mM phenylmethylsulfonyl fluoride (PMSF) and centrifuged for 30 min. at 20,000 x g. Polyacrylamide gel electrophoresis of the pellet and supernatant fractions showed that the bulk of the hmulti-CSF proteins is stored in the bacteria in an insoluble form.

The pellet was re-extracted with 0.5% NP-40 buffer and finally solubilized with 8 M urea 0.1 M Tris/HCl, pH 8.0 and 5 mM dithiothreitol. Thus, an extensive purification of the fusion proteins was achieved (Figure 9).

As shown in the figure, inclusion bodies from bacteria (E. coli) containing pGB/IL-301 and pGB/IL-302 were isolated as described. Lanes 1 show the 0.2% NP40 supernatant (sample corresponds to 0.1 ml of the original bacterial culture). Lanes 2 show the 0.5% NP40 supernatant (0.2 ml) and lanes 3 the pellet solubilized in 8 M urea buffer (A: 0.05 ml; B: 0.2 ml). The proteins were separated on a 13.5% SDS-polyacrylamide gel and stained with Coomassie Brilliant Blue. Molecular weights (in kd) of marker proteins (lane M) are denoted on the right. The human multi-CSF fusion proteins are indicated by arrows. The fusion protein encoded by pGB/IL-301 has a MW as expected of about 20 kd; that produced from pGB/IL-302, of about 16 kd.

E. Determination of Biological Activity of Bacterial hmulti-CSF Preparations

Bacterial protein preparations were diluted in alpha medium containing 1% bovine serum albumin, filter sterilized and assayed in the AML blast proliferation assay. Diluted samples were added to purified AML blasts and cultured for four days. DNA synthesis was measured using ^{3}H thymidine as described (51). One unit per ml is defined as the amount of hmulti-CSF required for half maximal proliferation of AML blasts. Figure 10 shows this titration. Various dilutions of the urea extracted protein preparation of bacteria containing the plasmid pGB/IL-302, were assayed for the stimulation of AML blast proliferation using ^{3}H-thymidine. The fusion protein concentration of this protein preparation was 33 µg/ml. Based

* Trade-mark

on the presented titration curve, the activity of this preparation is 16,000 units/ml.

The amount of bacterial fusion protein in the preparations was estimated from polyacrylamide gel-electrophoresis and used for calculating specific activities.

The results are shown in the following table:

Table 1

Biological Activity of Bacterial hmulti-CSF Preparations

	Mr ($\times 10^{-3}$) lacZ/hmulti (1)	ug protein per ml (2)	units per ml (3)	Specific activity units per mg IL-3
pGB/IL-301	20	20	45	4,500
pGB/IL-302/303	16	5	2400	480,000
pGB/IL-304	18	ND(4)	18	-
pGB/IL-305	16	1	300	300,000
pGB/IL-306	15	ND	70	ND

1. Approximate molecular weights are estimated from the DNA sequence of the fusion protein (Figure 8).
2. IL-3 concentrations were estimated on SDS-polyacrylamide gel and calculated per ml of starting culture.
3. Activity of urea solubilized protein was determined in the AML proliferation assay and is expressed per ml of starting culture.
4. Not determined.

From these results it was concluded that human multi-CSF expressed as a fusion protein in E. coli was obtained in biologically active form. The results show that changes introduced into the N-terminus of the fusion proteins may influence the specific activity of these proteins.

Example 4

Preparation of Antibody Preparations Capable of Immunospecific Reaction with Human IL-3 Protein

A. Polyclonal Rabbit Anti-Human IL-3 Antiserum.

A preparative gel was made from a lysate of *E. coli* containing the plasmid pGB/IL-301. The 20 kd band with the IL-3 fusion protein was sliced out, minced in saline with a mortar and emulsified in a 1:1 ratio in Complete Freund's Adjuvant containing 1 mg of *Mycobacterium tuberculosis* H37RA per ml. New Zealand White rabbits (spf) were immunized with 1 ml of the emulsion (with ± 100 µg IL-3 fusion protein) divided over 5 injection sites (2 x i.m. in the thighs, 3 x s.c. on the back). Booster injections of the same antigen in Incomplete Freund's Adjuvant were given at week 2, 4 and 6. Serum was collected at week 8 by venapuncture from the ear.

One volume of serum was absorbed with 9 volumes of sonicated pUC8 containing *E. coli* (overnight at 4°C) to remove nonspecific antibodies. Immunoblotting of all IL-3 constructs made in *E. coli*, *B. licheniformis*, *B. subtilis*, *S. cerevisiae* and *K. lactis* showed immunospecific reaction with the absorbed sera at a dilution of 1 in 6500.

Some of these results are shown in Figure 11. The proteins were isolated from the recombinant hosts as described above and were separated on a 13.5% polyacrylamide gel and blotted onto a nitrocellulose membrane. Lane 1: *E. coli* containing pTZ18R (control); Lane 2: pGB/IL-301; Lane 3: pGB/IL-301; Lane 4: pGB/IL-302; Lane 5: pUC19 (control); Lane 6: pGB/IL-301; Lane 7: pGB-IL-302. Lanes 6 and 7 show proteins present in the pellet after the sonification of the bacteria. Lanes 3, 4 and 5 show proteins present in the pellet after the first washing step. Lanes 1 and 2 show the final urea-solubilized protein fractions.

The arrows show the fusion proteins (of the expected size) expressed from pGB/IL-301 and pGB/IL-302.

Figure 12A shows the inhibition of IL-3 dependent proliferation of AML blast cells by anti-IL-3 antiserum.

Figure 12B shows that the preimmune serum does not affect the action of IL-3 on AML blast cell proliferation. In both panels, ▲ = IL-3 at 10 U/ml; ■ = IL-3 at 1U/ml; ● = control, no addition.

Figure 12A shows IL-3 dependent growth in the AML blast proliferant assay (51) was inhibited by the sera in a dose dependent manner; Figure 12B shows preimmune sera do not have this effect. As control, GM-CSF dependent growth was unaffected by these sera in the same assay (Figure 12A where ◆ = GM-CSF at 100 U/ml.)

B. Monoclonal Mouse Anti-Human IL-3 Antibodies

Balb/C mice were immunized with 3 x 0.1 ml (s.c.) of the same emulsion as used for the rabbits. A booster (0.1 ml i.p.) of antigen in Incomplete Freund's Adjuvant was given at week 2 and three days later spleen lymphocytes were fused with SP2/0 myeloma cells according to standard procedures (65). Hybridoma supernates were screened in the Enzyme Linked Immunosorbent Assay, using a lysate of E. coli pGB/IL-302 (containing the 17 kd IL-3 fusion product) as a positive control and a lysate of E. coli pUC8 as negative control. In total, 29 IL-3 hybridoma cultures secreting antibodies specific for IL-3 were selected and stabilized.

Example 5

Construction of Bacillus expression vectors

General cloning techniques were used (36).

A. Construction of pGB/IL-307 (Figure 13)

For construction of pGB/IL-307 the SmaI fragment of pLB4 carrying the hmulti-CSF gene, was ligated into PvuII digested pUB110 (54). After transformation to competent cells (56) of DB105 (a spo⁻ derivative of the protease deficient strain DB104 (55)), two clones were obtained, as expected: the fragment was cloned in both orientations. The plasmid that harbored the fragment in the correct orientation with respect

to the so-called "Hpa II promoter" (57) was called pGB/IL-307. In this case a fusion protein will be made (see Figure 13).

B. Construction of pGB/IL-310

A hmulti-CSF expression plasmid was prepared as described below.

1. Promoter cloning (Figure 14).

For expression in Bacillus a synthetic σ^{43} promoter as described (58) is used (the promoter used to be called σ^{55}).

Plasmids pPROM55s (58), the promoter containing plasmid, and pGPA14 (59) were digested with EcoRI and XbaI. The promoter fragment was ligated into the vector fragment, which had been purified on an agarose gel. After transformation to E. coli (JM 101), the correct plasmid was obtained and called pGB/IL-308 (Fig. 14).

2. Introduction of a synthetic oligonucleotide into pGB/IL-308 (Figure 15).

A synthetic oligonucleotide comprising the nucleotides 39-158 and 484-546 of hmulti-CSF, a 5' terminal SalI recognition sequence and a 3' terminal XmaIII site was ligated into SalI-XmaIII digested pGB/IL-308. The ligation mixture was introduced into JM101. After analysis of a number of transformants, the correct plasmid was found, pGB/IL-309.

3. Introduction of hIL3 (Figure 16).

After transformation to and isolation from B. subtilis DB105, the plasmid pGB/IL-309 was digested with XmaIII. The recessed ends were filled in with Klenow polymerase, and the plasmid was cleaved with ClaI. The plasmid pGB/IL-307 was digested with AvaI, the ends filled in with Klenow and then digested with ClaI. Subsequently, the hmulti-CSF containing fragment was ligated into the pGB/IL-309 fragment and transformed to JM101. The resulting plasmid was called pGB/IL-310 (Figure 16). This plasmid

harbored the hIL-3 gene with its own signal sequence. After isolation of the correct plasmid, it was also introduced into B. subtilis DB105.

C. Construction of pGB/IL-311 and pGB/IL-312 (Figures 17, 18)

pGB/IL-310 was partially digested with HindIII and totally with PvuII. The two hmulti-CSF containing PvuII-digested with HindIII and SmaI.

Figure 17 shows the nucleotide sequence of plasmid pBHA1. The plasmid consists of positions 11-105 and 121-215; bacteriophage FD terminator (double): positions 221-307; a part of plasmid pBR322 (viz. positions 2069-2153): positions 313-768; bacteriophage F1, origin of replication (viz. positions 5482-5943): positions 772-2571; part of plasmid pBR322, viz. the origin of replication and the beta-lactamase gene: positions 2572-2685; transposon Tn903, complete genome: positions 2719-2772; tryptophan terminator (double): positions 2773-3729; transposon Tn9, the chloramphenicolacetyltransferase gene. The nucleotides at position 3005 (A), 3038 (C), 3302 (A) and 3409 (A) differ from the wild type cat coding sequence. These mutations were introduced so as to eliminate the NcoI, BalI, EcoRI and PvuII sites: positions 3730-3804; multiple cloning site: positions 3807-7264; part of plasmid pUB110, viz. the replication function and kanamycin resistance gene (EcoRI-PvuII fragment) (66, 67): positions 7267-7331; multiple cloning site. The fragments wer put together by known cloning techniques, e.g. filling in of sticky ends with Klenow, adapter cloning, etc. All data were derived from GenbankR, National Nucleic Acid Sequence Data Bank, NIH, USA.

After transformation to JM101 and analysis of a number of ampicillin resistant colonies, two different plasmids were found: pGB/IL-312, which harbored the complete gene with complete control sequences, and pGB/IL-311, which contained the complete gene and the promoter lacking the -35 region in the other orientation (see Figure 18).

pGB/IL-311 has been transformed to B. subtilis DB105 and B. licheniformis strain T399 (Δamy, spo⁻, exo-

protease negative, rif^r, see ref. 68, where this strain is named T9).

D. Construction of pGB/IL-313 (Figure 19).

In order to obtain a smaller plasmid, with the hmulti-CSF gene behind the "HpaII promoter", pGB/IL-312 was digested with BamHI and religated. The ligaton mixture was transformed into DB105 competent cells. A number of neomycin resistant colonies were analysed and the correct plasmid was obtained. The plasmid was called pGB/IL-313.

E. Construction of pGB/IL-317 (Figure 20)

In order to clone the hmulti-CSF gene behind the B. licheniformis alpha-amylase transcriptional and translational initiation region and signal sequence, one of the earlier described pOL5-delta vectors (68) was used, viz. pOL5-2 delta. Besides the alpha-amylase signal sequence (29 amino acids long) this plasmid harbors one amino acid of the alpha-amylase mature sequence (an Ala) followed by a multiple cloning site: EcoRI-XmaIII-XmaI-SalI-HindIII (68).

The SalI-PvuII fragment of plasmid pGB/IL-310 containing the hmulti-CSF gene was ligated into the SalI-PvuII digested pOL5-2 delta vector and transformed to DB105. The resulting plasmid was called pGB/IL-317 (Figure 20). The hIL-3 gene still harbors its own signal sequence on this plasmid. The plasmid was also introduced into B. licheniformis T399.

F. Expression of Five Expression Plasmids in Bacillus Strains

B. subtilis and B. licheniformis strains carrying the expression plasmids mentioned below were grown in TSB medium containing 20 µg/ml neomycin or 10 µg/ml erythromycin at 37°C (for 16-24 hours); 300 µg/ml of the culture was centrifuged. The pellet was resuspended in sample buffer and analyzed using polyacrylamide gel-electrophoresis followed by Western blotting. The supernatant was TCA precipitated, and the pellet was resuspended in sample buffer. Both supernatant and pellet were analyzed for IL-3 protein (see Table 2).

To determine the biological activity of the produced proteins, the following steps were carried out: The

cellpellets were resuspended in a buffer containing 0.1 M Tris/HCl pH 8.0 and 10 mM $MgCl_2$. Lysozyme was added to a final concentration of 1 mg/ml and PMSF to a final concentration of 1 mM. The solution was incubated for 30 min. at 37°C. Subsequently DNase (final concentration 20 µg/ml) was added and the solution was incubated for 15 min. at 20°C. Finally, the biological activity of this preparation as well as of the supernatant of the cultured cells was determined as described. The results are shown in Table 2.

Table 2

Expression of the Bacillus Vectors

Plasmid	Strain	MW IL-3 Pellet (kd)	MW IL-3 supernatant (kd)	Biological activity pellet	Biological activity supernatant
pGB/IL-307	DB105	21	-	+	-
pGB/IL-310	DB105	15;17	15;17	-	-
pGB/IL-311	DB105	12.5;15	-	+	-
	T399	-	-	+	-
pGB/IL-313	DB105	15;17	12.5;15	+	-
	T399	-	-	+	-
pGB/IL-317	DB105	12.5;15 17;20	12.5;15 17	+	+
	T399	12.5;15 17;20	12.5;15 17	+	+

It can be concluded, that in B. subtilis, using pGB/IL-307, a fusion protein is made that has IL-3 activity. When the human IL-3 gene only contains its own signal sequence no significant secretion of human IL-3 is obtained. All IL-3 activity is found intracellularly. In those cases it seems that besides precursor IL-3 mature IL-3 (15 kd) has been formed in the cell. Thus, some transport across the membrane might have taken place, but the protein is not transported

across the cell wall. However, using the alpha-amylase regulation and secretion signals (pGB/IL-317) most of the IL-3 activity appeared to be secreted into the culture medium. Besides a degradation product, two proteins are detected in the supernatant, one of about 15 kd and one of about 17 kd, most probably mature IL-3 and precursor IL-3, respectively. These data indicate that both processing sites, viz. the alpha-amylase and the hmulti-CSF processing site, are used. In the cell the most abundant product is precursor IL-3 containing the alpha-amylase signal sequence (the 20 kd protein) as shown by Western blotting. Sometimes a degradation product is detected.

Example 6

Construction of Kluyveromyces lactis expression vectors

A. Construction of pGB/IL-316

A DNA fragment comprising the Tn5 gene (61) conferring resistance to gentamycin G418, under the direction of the alcohol dehydrogenase I (ADHI) promoter from *S. cerevisiae*, similar to that described by Bennetzen and Hall (62), was inserted into the SmaI site of pUC19 (63). An *E. coli* strain containing the obtained plasmid, pUC-G418, was deposited with CBS on December 4, 1987 under CBS 872.87.

Into the XbaI-HindIII cleaved pUC-G418 vector a XbaI-HindIII fragment from plasmid pGB903 (64) containing the *K. lactis* lactase promoter and calf prochymosin DNA was inserted, resulting in plasmid pGB/IL-314.

The SalI-HindIII fragment from this plasmid was replaced by a synthetic DNA fragment containing a small multiple cloning site and the lactase terminator (see Figures 21, 22). The resulting plasmid is designated pGB/IL-315.

In the SacII-XhoI cleaved pGB/IL-315 vector the following fragments were ligated:

1. The SacII-XbaI fragment from pKS105 (Canadian Pat. Appln. No. 573,343 filed July 28, 1988), carrying the 3' part of the lactase promoter and the 5' part of the alpha-factor signal sequence

of S. cerevisiae.

2. A synthetic oligonucleotide comprising the 3' part of the alpha-factor signal sequence starting at the XbaI site and the 5' part of the mature hIL-3 cDNA sequence upto the 5' half of the HpaI site (aa-residue 14).

3. The HpaI-XhoI fragment carrying most part of the hIL-3 cDNA sequence (residue 15-133 plus the 3' non-coding region). The resulting plasmid, designated pGB/IL-316, is depicted schematically in Figure 21. The complete vector sequence from the SacII site in the lactase promoter sequence up to the HindIII site at the end of the synthetic terminator is given in Figure 22.

Figure 22 shows the nucleotide sequence of plasmid pGB/IL-316 between the unique Sac II site in the lactase promoter and the Hind III site behind the terminator (residues 4457 to 7204). Residues 4457 to 6100 comprise the lactase promotor sequence. Residues 6101 to 6355 comprise the alpha factor signal sequence. Residues 6356 to 7115 comprise the sequence for mature human IL-3 plus the 3' noncoding cDNA sequence. Residues 7116 to 7204 comprise the synthetic terminator sequence.

B. Construction of pGB/IL-318

An expression vector similar to pGB/IL-316 was constructed in which the coding information for the alpha factor signal sequence of S. cerevisiae was replaced by the alpha-factor signal sequence of K. lactis (64). The remaining part of the plasmid is identical to pGB/IL-316. The sequence of pGB/IL-318 between the SacII site in the lactase promoter and the HindIII site behind the terminator (residues 4457 to 7190) is given in Figure 23.

Residues 4457 to 6087 comprise the sequence of the lactase promoter and a small linker sequence. Residues 6088 to 6342 comprise the K. lactis alpha factor signal sequence. Residues 6343 to 7102 comprise the sequence for mature human IL-3 plus the 3' noncoding cDNA sequence. Residues 7103 to 7190 comprise the synthetic terminator sequence.

C. Transformation of Kluyveromyces Lactis and Analysis of Secreted hIL-3

Plasmids pGB/IL-316 and pGB/IL-318 were digested at the unique SacII site in the lactase promoter region, and used to transform K. lactis strain CBS 2360 (see 64). Integration of the plasmids is thus targeted to the chromosomal lactase gene promoter region. The resulting G418 resistant transformants were grown to saturation in liquid YEPD medium, and the culture supernatants and cell lysates were assayed for IL-3 activity using the AML cell DNA synthesis assay.

Virtually all IL-3 appeared to be secreted into the culture medium, and to be active. The proteins from the culture supernatant were precipitated using ethanol and analyzed using denaturing polyacrylamide gel-electrophoresis followed by Western blotting. The predominant product has an apparent MW of about 21 kd, whereas also a distinct band at about 15 kd is observed. The latter product most probably corresponds to the mature unglycosylated IL-3, whereas the 21 kd product is the product carrying core glycosylation at the two potential glycosylation sites. Incubation with Endoglycosidase H results in a protein migrating in the 15 kd range, suggesting that all IL-3 is processed correctly during the secretion process and that the bulk of the protein is being glycosylated.

Example 7

Construction of a Saccharomyces Cerevisiae Expression Vector

A. Construction of pGB/IL-319

First an expression vector called pGB/TEFact was constructed. On this pTZ18R (Pharmacia) derived plasmid the S. cerevisiae translation elongation factor (EF-1alpha) promoter sequence, which was cloned and sequenced as described (73,74), is coupled by means of a small SalI-BglII-XhoI linker to the S. cerevisiae actin transcription terminator sequence (75), which was synthesized using an Applied Biosystems DNA synthesizer. The sequence of the expression cassette is given

in Figure 24. Residues 1 to 949 comprise the EF-1alpha promoter. Residues 950 to 967 comprise the sequence of the SalI-BglII-XhoI linker. Residues 968 to 1113 comprise the actin terminator sequence.

The unique SmaI site in pGB/TEFact was used to introduce the G418 resistance cassette described in Example 6. The resulting plasmid was called pGB/TEFactG418.

Finally, the hIL-3 expression vector pGB/IL-318 was constructed by introduction of the following DNA sequences into the SalI-XhoI cleaved pGB/TEFactG418 plasmid:

- The SalI-NruI fragment from pGB/IL-316 carrying the S. cerevisiae alpha factor signal sequence and the hIL-3 coding sequence upto the NruI site.

- A synthetic NruI-XhoI DNA fragment comprising the remaining nucleotides coding for hIL-3 and the XhoI recognition sequence immediately following the TGA stopcodon.

B. Transformation of Saccharomyces Cerevisiae and Analysis of Secreted hIL-3

Plasmid pGB/IL-319 was cleaved at the unique EcoRI site in the EF-1α promoter. Integration of the plasmid is thus targeted to the chromosomal EF-1α region. S. cerevisiae wild type strain D273-103 (alpha; ATCC 25657) was transformed as described for K. lactis (64). The G418-resistant colonies were picked and transformants were given to saturation in liquid YEPD medium. The culture supernatant was assayed for hIL-3 activity using the AML assay. The protein produced by S. cerevisiae was found biologically active.

The proteins from the supernatant were precipitated using ethanol and subsequently analyzed by polyacrulamide gel-electrophoresis followed by Western blotting. Two prominent products could be distinguished on the Western blot, a 21 kd glycosylated product and an unglycolysed product of about 15 kd.

REFERENCES

1 Metcalf D., Blood 67, 257-267 (1986).

2 Whetton A.D. and Dexter T.M. TIBS 11, 207-211 (1986).

3 Wagemaker G., In "Bone Marrow Transplantation" (eds. Van Bekkum D.W. and Lowenberg B.) Marcel Dekker Inc. New York 1-72 (1985).

4 Dorssers L. et. al., Exp. Hematol. 12, 357, 1984.

5 Till J.E. and McCulloch E.A., Radiat. Res. 14, 213-222 (1961).

6 Hapel A.J., et. al., Blood 65, 1453-1459 (1985).

7 Scheven B.A.A., Nature 321, 79-81 (1986).

8 Garland J.M. and Crompton S. Exp. Hematol. 11, 757-761 (1983).

9 Stanley E.R. et. al., Cell 45, 667-674 (1986).

10 Kreigler A.B. et. al., Blood 60, 503-508 (1982).

11 Fung M.C. et. al., Nature 307, 233-237 (1984).

12 Yokata T. et. al., Proc. Natl. Acad. Sci. USA, 81, 1070-1074 (1984).

13 Lowenberg B. and Dicke K.A., Exp. Hematol. 5, 319-331 (1977).

14 Wagemaker G. and Peters M.F., Cell. Tiss. Kinet. 11, 45-56 (1978).

15 Ihle J.N., et. al., In "advances in viral oncology", vol. 4 (ed Klein G.) 95-137, Raven Press, New York 1984.

16 Fauser A.A. and Messner H.A. Blood 52, 1243-1248 (1978).

17 Lowenberg B. et. al., Leuk. Res. 4, 143-149 (1980).

18 Lowenberg B. et. al., Blood 59, 64-645 (1982).

19 Buick R.N. et. al., Blood 54, 95-104 (1979).

20 Huynh T.V. et. al., In "DNA cloning", vol. 1 (Ed. Glover D.M.) IRL press, Oxford 45-78 (1985).

21 Kozak M. Cell 44, 283-292 (1986).

22 Von Heijne G. Eur J. Biochem 133, 17-21 (1983).

23 Perlman D. and Halvorson H.O., J. Mol. Biol. 167, 391-409 (1983).

24 Shaw G. and Kamen R. Cell 46, 659-667 (1986).

25 Schrader J.W., et. al., Proc. Natl. Acad. Sci. USA 83, 2458-2462 (1986).

26 March C.J., et. al., Nature 315, 641-647 (1985).
27 Higashi Y. et. al., J. Biol. Chem. 358, 9522-9529 (1983).
28 Dijkema R. et. al., EMBO J. 4, 761-767 (1985).
29 Zwarthoff E.C. et. al., Nucleic Acid Res. 13, 791-804 (1985).
30 Clark-Lewis I. et. al., Science 231, 134-139 (1986).
31 Kindler V. et. al., Proc. Natl. Acad. Sci. USA 83, 1001-1005 (1986).
32 DeLamarter J.F. et. al., EMBO J. 10, 2575-2581 (1985).
33 Lemischka I.R. et. al., Cell 45, 917-927 (1986).
34 Yu-Chung Yang et. al., Cell 47, 3-10 (1986).
35 Miyatake S. et. al., Proc. Natl. Acad. Sci. USA 82, 316-320 (1985).
36 Maniatis T. et. al., In "Molecular Cloning, A. laboratory manual". Cold Spring Harbor Laboratories, New York (1982).
37 Gubler U. and Hofmann B.J., Gene 25, 263-269 (1983).
38 Feinberg A.P. and Vogelstein B. Anal. Biochem. 132, 6-13 (1983).
39 Sanger F. et. al., Proc. Natl. Acad. Sci. USA 74, 5463 (1977).
40 Queen C. and Korn L.J. Nucleic Acid Res. 12, 581-599 (1984).
41 Staden R. Nucleic Acid Res. 10, 2951-2961 (1982).
42 Devereux J., et. al., Nucleic Acid Res. 12, 387-395 (1984).
43 Lipman D.J. and Pearson W.R. Science 227, 1435-1441 (1985).
44 Subramani S. and Southern P.J., Anal. Bioch. 135, 1-15 (1983).
45 Wigler M., et. al., Cell 14, 725-731 (1978).
46 Majdic O., et. al., Int. J. Cancer 33, 617-623 (1984).
47 Lowenberg B. and Bauman J.G.J. Blood 66, 1225-1232 (1984).
48 Delwel R., et. al., Blood 68, 41-45 (1986)
49 Swart K. et. al., Blood 59, 816-821 (1982).
50 Swart K. and Lowenberg B. Cancer Res. 44, 657-660 (1984).
51 Touw I. et. al., Blood 68, 1088-1094 (1986).
52 Vieira, J. and Messing J., Gene 19, 259-268 (1982)
53 Osinga, K.A. et al., Nucleic Acids Res. 11, 8595-8608 (1983)

54. Gryczan, T.C. et al., J. Bacteriology 134, 318-329 (1978).
55. Kawamura, F. and Doi, R.H., J. Bacteriology 160, 442-444 (1984).
56. Bron, S. and Venema, G., Mutat. Res. 15, 1-10 (1972).
57. Zyprian, E. and Matzura, H., DNA 5, 219-225 (1986).
58. EPA 0224294, published June 3, 1987.
59. EPA 0244042, published November 4, 1987.
60. Stanssens P. et al., In "Protein Engineering and Site-Directed Mutagenesis". Twenty-Fourth Harden Conference. Program and Abstracts (1985) (Fersht, A.R. and Winter, G., edts).
61. Reiss, B. et al., EMBO J. 3, 3317-3322 (1984).
62. Bennetzen, J.L. and Hall, B.D., J. Biol. Chem. 257, 3018-3025 (1982).
63. Yanisch-Perron, C. et al., Gene 33, 103-119 (1985).
64. Canadian Appl. No. 573,343, filed July 28, 1988.
65. Salfre, S. and Milstein, C., Meth Enz 73, 3-75 (1981).
66. McKenzie, T. et al., Plasmid 15, 93-103 (1986).
67. McKenzie, T. et al., Plasmid 17, 83-85 (1987).
68. Canadian Pat. Appl. No. 542,396, filed July 17, 1987.
69. Chen, E.Y. et al., Nature 299, 529-534 (1982).
70. Law, M-F. et al., Mol. Cell Biol. 3, 2110-2115 (1983).
71. Hirt, B., J. Mol. Biol. 26, 365-367 (1967).
72. Suarez Rendueles, M.P. et al., FEBS Lett. 131, 296-300 (1981).
73. Najata, S. et al., EMBO J. 3, 1825-1830 (1984).
74. Nagashima, K. et al., Gene 45, 265-273 (1986).
75. Gallwitz, D. and Sures, I., Proc. Natl. Acad. Sci. USA 77, 2546-2550 (1980).

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

1. An expression system, operable in a host cell, comprising control sequences operably associated with a DNA sequence which encodes human interleukin 3 having the amino acid sequence

Ala Pro Met Thr Gln Thr Thr Pro Leu Lys Thr Ser Trp Val Asn Cys
Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu
Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu
Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys Asn
Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His Pro
Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr
Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu
Ser Leu Ala Ile Phe.

2. A method for producing human interleukin 3 having the amino acid sequence

Ala Pro Met Thr Gln Thr Thr Pro Leu Lys Thr Ser Trp Val Asn Cys
Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu
Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu
Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys Asn
Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His Pro
Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr
Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu
Ser Leu Ala Ile Phe,

comprising:

(i) introducing into a host cell, an expression system comprising control sequences operatively associated with a DNA sequence encoding said interleukin 3;

H

(ii) growing said host cell in a nutrient medium under suitable conditions whereby said interleukin 3 is produced; and

(iii) recovering said interleukin 3.

3. Human interleukin 3 having the amino acid sequence

Ala Pro Met Thr Gln Thr Thr Pro Leu Lys Thr Ser Trp Val Asn Cys
Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu
Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu
Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys Asn
Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His Pro
Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr
Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu
Ser Leu Ala Ile Phe.

4. Use of human interleukin 3 having the amino acid sequence

Ala Pro Met Thr Gln Thr Thr Pro Leu Lys Thr Ser Trp Val Asn Cys
Ser Asn Met Ile Asp Glu Ile Ile Thr His Leu Lys Gln Pro Pro Leu
Pro Leu Leu Asp Phe Asn Asn Leu Asn Gly Glu Asp Gln Asp Ile Leu
Met Glu Asn Asn Leu Arg Arg Pro Asn Leu Glu Ala Phe Asn Arg Ala
Val Lys Ser Leu Gln Asn Ala Ser Ala Ile Glu Ser Ile Leu Lys Asn
Leu Leu Pro Cys Leu Pro Leu Ala Thr Ala Ala Pro Thr Arg His Pro
Ile His Ile Lys Asp Gly Asp Trp Asn Glu Phe Arg Arg Lys Leu Thr
Phe Tyr Leu Lys Thr Leu Glu Asn Ala Gln Ala Gln Gln Thr Thr Leu
Ser Leu Ala Ile Phe,

for treating a diseased state characterized by a deficiency in the level of hematopoietic cells.

5. An expression system operable in a recombinant host which expression system consists essentially of a DNA sequence encoding purified human IL-3, having the amino acid

sequence numbered 1 to 133 in sequence "H" of Figure 1, operably linked to control sequences effective in said host.

6. The expression system of claim 5, wherein the DNA encoding human IL-3 contains no introns.

7. The expression system of claim 5, wherein the control sequences comprise a promoter selected from the group consisting of the lac promoter, the HpaII promoter, the α43 promoter, the alpha-amylase promoter, the EF-1 alpha promoter and the SV40 promoter.

8. The expression system of claim 6, wherein the control sequences comprise a promoter selected from the group consisting of the lac promoter, the HpaII promoter, the α43 promoter, the alpha-amylase promoter, the EF-1 alpha promoter and the SV40 promoter.

9. A vector which is pGB/IL-300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318 or 319.

10. A vector selected from the group of pLB4 and pLB4/BPV.

11. A method for producing purified human IL-3, having the amino acid sequence numbered 1 to 133 in sequence "H" of Figure 1, by a host cell, said method comprising:

introducing into said host cell a DNA construct comprising an expression cassette which comprises in the direction of transcription a transcriptional initiation regulatory region functional in said host cell;

a DNA sequence encoding human IL-3; and

a transcriptional termination regulatory region functional in said host cell;

growing said host cell comprising said DNA construct in a nutrient medium under suitable culture conditions, whereby human IL-3 is produced; and

recovering the human IL-3 product.

12. A method according to claim 11, wherein said host cell is a transformed living host cell containing genetic material derived from recombinant DNA material and coding for purified human IL-3 having the amino acid sequence numbered 1 to 133 in sequence "H" of Figure 1.

13. A method according to claim 12, wherein said transformed living host cell is selected from the group consisting of yeasts, bacteria, fungi and tissue culture cells.

14. A method according to claim 13, wherein said transformed yeast host cell is selected from the group of Saccharomyces and Kluyveromyces.

15. A method according to claim 13, wherein the transformed bacteria host cell is selected from the group of E. coli and Bacillus.

16. A method according to claim 13, wherein the transformed tissue culture host cell is selected from the group COS, C127 and insect cells.

17. A method according to claim 11, wherein said host cell is a transformed living host cell containing genetic material derived from recombinant DNA material and coding for purified human IL-3 having the amino acid sequence numbered 1

H

to 133 in sequence "H" of Figure 1, transformed with the expression system of claim 5, 6, 7 or 8.

18. A method according to claim 17, wherein said transformed living host cell is selected from the group consisting of yeasts, bacteria, fungi and tissue culture cells.

19. A method according to claim 18, wherein said transformed yeast host cell is selected from the group of Saccharomyces and Kluyveromyces.

20. A method according to claim 18, wherein said transformed bacteria host cell is selected from the group of E. coli and Bacillus.

21. A method according to claim 18, wherein the transformed tissue culture host cell is selected from the group COS, C127 and insect cells.

22. A purified protein having purified human IL-3 activity, substantially free of other substances accompanying said protein and said human IL-3 having the amino acid sequence numbered 1 to 133 in sequence "H" of Figure 1.

23. The protein of claim 22, which is produced by the recombinant expression of the DNA sequence shown as encoding amino acids 1 to 133 in sequence "H" of Figure 1 or the naturally occurring mutants thereof.

24. The protein of claim 22, in glycosylated or unglycosylated form.

H

25. The protein of claim 23, in glycosylated or unglycosylated form.

26. The protein of claim 22, 23 or 24 produced in a transformed living host cell containing genetic material derived from recombinant DNA material and coding for purified human IL-3 having the amino acid sequence numbered 1 to 133 in sequence "H" of Figure 1.

27. The protein of claim 26, wherein the transformed living host cell is selected from the group consisting of yeasts, bacteria, fungi and tissue culture cells.

28. The protein of claim 27, wherein the transformed yeast host cell is selected from the group of Saccharomyces and Kluyveromyces.

29. The protein of claim 27, wherein the transformed bacteria host cell is selected form the group of E. coli and Bacillus.

30. The protein of claim 27, wherein the transformed tissue culture host cell is selected from the group COS, C127 and insect cells.

31. The protein of claim 22, 23 or 24 produced in a host cell wherein said host cell is a transformed living host cell containing genetic material derived from recombinant DNA material and coding for purified human IL-3 having the amino acid sequence numbered 1 to 133 in sequence "H" of Figure 1, transformed with the expression system of claim 5, 6, 7 or 8.

32. The protein of claim 31, wherein said transformed living host cell is selected from the group consisting of yeasts, bacteria, fungi and tissue culture cells.

33. The protein of claim 32, wherein said transformed yeast host cell is selected from the group of Saccharomyces and Kluyveromyces.

34. The protein of claim 32, wherein said transformed bacteria host cell is selected from the group of E. coli and Bacillus.

35. The protein of claim 32, wherein the transformed tissue culture host cell is selected from the group COS, C127 and insect cells.

36. An antibody preparation capable of immunospecific reaction with human IL-3 having the amino acid sequence numbered 1 to 133 in sequence "H" of Figure 1.

37. A method to produce an antibody preparation capable of immunospecific reaction with human IL-3 which comprises injecting a vertebrate host with the purified human IL-3 of claim 22, 23, 24 or 25.

38. A method to produce an antibody preparation capable of immunospecific reaction with human IL-3 which comprises injecting a vertebrate host with the purified human IL-3 of any one of claims 26, 27, 28, 29 or 30.

1/26



FIGURE 1

Eitan, Hoshen & Hirsch
PATENT AGENTS



FIGURE 2

Cohen, Pontani, Lieberman & Pavane
PATENT AGENTS



FIGURE 3



FIGURE 4

Cole, Hirsch, Klauzinski

PATENT AGENTS



FIGURE 5

PATENT AGENTS

5/26

```
          EcoRI SacI  KpnI SmaI BamHI XbaI SalI  PstI  SphI  HindIII
pTZ18R    gggaattcgagctcggtacccggggatcctctagagtcgacctgcaggcatgcaagcttg

          EcoRI SacI  EcoRV HindIII BglII     BamHI XbaI  SalI  PstI
pT1       gggaattcgagctcgatatcaagcttagatctcgaggggatcctctagagtcgacctgcag

          SphI        NdeI
          gcatgcaagctgcatatgcagcttg
```

FIGURE 6

Eaton, Hooper & Harcourt

PATENT AGENTS



FIGURE 7

PATENT AGENTS

pGB/IL-301

Met Thr Met Ile Thr Asn Ser Arg Gly Ser Gly Pro
atg acc atg att acg aat tcc cgg gga tct gGA CCA

Glu Gln Asp Arg Val Pro Pro Ala Asp Pro Asn Met
GAA CAA GAC AGA GTG CCT CCT GCC GAT CCA AAC ATG

Ser Arg Leu Pro Val Leu Leu Leu Leu Gln Leu Leu
AGC CGC CTG CCC GTC CTG CTC CTG CTC CAA CTC CTG

Val Arg Pro Gly Leu Gln Ala[1]Pro Met Thr Gln Thr
GTC CGC CCC GGA CTC CAA GCT CCC ATG ACC CAG ACA

Thr Pro Leu Lys Thr Ser Trp Val Asn Cys Ser Asn
ACG CCC TTG AAG ACA AGC TGG GTT AAC TGC TCT AAC

Met Ile Asp
ATG ATC GAT

pGB/IL-302

Met Thr Met Ile Thr Asn Ser Arg Gly Ser Ser Arg
atg acc atg att acg aat tcc cgg gga tcc tct aga

Val Asp Pro[2]Met Thr Gln Thr Thr Pro Leu Lys Thr
gtc gac CCC ATG ACC CAG ACA ACG CCC TTG AAG ACA

Ser Arg Val Asn Cys Ser Asn Met Ile Asp
AGC CGG GTT AAC TGC TCT AAC ATG ATC GAT

pGB/IL-303

Met Thr Met Ile Thr Asn Ser Arg Gly Ser Ser Arg
atg acc atg att acg aat tcc cgg gga tcc tct aga

Val Asp Pro[2]Met Thr Gln Thr Thr Pro Pro Lys Thr
gtc gac CCC ATG ACC CAG ACA ACG CCC CCG AAG ACA

Ser Arg Val Asn Cys Ser Asn Met Ile Asp
AGC CGG GTT AAC TGC TCT AAC ATG ATC GAT

pGB/IL-304

Met Thr Met Ile Thr Asn Leu Ile Arg Leu Thr Ile
atg acc atg att acg aat tta ata cga ctc act ata

Gly Asn Ser Ser Ser Val Pro Gly Asp Pro Leu Glu
ggg aat tcg agc tcg gta ccc ggg gat cct cta gag

Ser Ile Asp Pro[2]Thr Thr Glu Thr Thr Pro Leu Lys
tcg atc gac CCC ACG ACC CAG ACA ACG CCC CTG AAG

Thr Ser Trp Val Asn Cys Ser Asn Met Ile Asp
ACA AGC TGG GTT AAC TGC TCT AAC ATG ATC GAT

FIGURE 8

Cohen, Hoshen & Hanscom

PATENT AGENTS

8/26

pGB/IL-305

Met Thr Met Ile Thr Asn Leu Ile Arg Leu Thr Ile
atg acc atg att acg aat tta ata cga ctc act ata

Gly Asn Ser Ser Ser Val Pro Gly Asp Pro Leu Glu
ggg aat tcg agc tcg gta ccc ggg gat cct cta gag

Asn[15]Cys Ser Asn Met Ile Asp
AAC TGC TCT AAC ATG ATC GAT

pGB/IL-306

Met Ala[1]Pro Met Thr Gln Thr Thr Pro Leu Lys Thr
atg GCT CCC ATG ACC CAG ACA ACG CCC TTG AAG ACA

Ser Trp Val Asn Cys Ser Asn Met Ile Asp
AGC TGG GTT AAC TGC TCT AAC ATG ATC GAT

FIGURE 8 (cont'd)

Cole, Hoffman & Hacker

PATENT AGENTS

pGB/IL-301 pGB/IL-302



FIGURE 9

Oslet Hoskin & Harcourt

PATENT AGENTS



FIGURE 10

PATENT AGENTS



FIGURE 11

PATENT AGENTS



FIGURE 12

PATENT AGENTS



*Sequence of the N-terminus of the fusion protein:

Met Ser Tyr Ala Val Cys Arg Met Glu Lys

Val Lys Ser Gly Val Pro Ser Ser Asn Ser Gly

Pro Glu Gln Asp Arg Val Pro Pro Ala Asp Pro

Asn Met Ser Arg Leu ..... Ala Pro .....
−19 +1
hIL-3 signal sequence hIL-3 mature sequence

FIGURE 13

PATENT AGENTS

13/26



FIGURE 14

Baker, Hudson & Keenan
PATENT AGENTS



FIGURE 15

Cushman Hoseley & Hayes

PATENT AGENTS



pIL-3:precursor gene human IL-3.

FIGURE 16

PATENT AGENTS



FIGURE 17

Cohen, Morton & Hammond

PATENT AGENTS



```
3160       3170       3180       3190       3200       3210       3220       3230       3240       3250       3260       3270       3280       3290       3300
CATCTTGCGAATATATGTGTAGAAACTGCCGGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGCTCATGGAAAACGGTGTAACAAGGGTGAACACTATCCCATATCACCAGCTCACCGTCTTTCATTGCCATAC

3310       3320       3330       3340       3350       3360       3370       3380       3390       3400       3410       3420       3430       3440       3450
GAAATTCCGGATGAGCATTCATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTATTTTTCTTTACGGTCTTTAAAAAGGCCGTAATATCCAGCTAAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATG

3460       3470       3480       3490       3500       3510       3520       3530       3540       3550       3560       3570       3580       3590       3600
CCTCAAAATGTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTCCATTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTTCATTATGGTGAAAGT

3610       3620       3630       3640       3650       3660       3670       3680       3690       3700       3710       3720       3730       3740       3750
TGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAAAAGTTGGCCCAGGGCTTCCCGGTATCAACAGGGACACCAGGATTTATTTATTCTGCGAAGTGATCTTCCGTCACAGGTATTTATTCGAAGACGAAAGGGCATCGCGCGC

3760       3770       3780       3790       3800       3810       3820       3830       3840       3850       3860       3870       3880       3890       3900
GGGGAATTCCCGGGAGAGCTCGATATCGCATGCGGTACCTCTAGAAGAAGCTTGGAGACAAGGTAAAGGATAAAACAGCACAATTCCAAGAAAAACACGATTTAGAACCTAAAAAGAACGAATTTGAACTAACTCATAACCGAGAGGTAA

3910       3920       3930       3940       3950       3960       3970       3980       3990       4000       4010       4020       4030       4040       4050
AAAAAGAACGAAGTCGAGATCAGGGAATGAGTTTATAAAATAAAAAAAGCACCTGAAAAGGTGTCTTTTTTTGATGGTTTTGAACTTGTTCTTTCTTATCTTGATACATATAGAAATAACGTCATTTTTATTTTAGTTGCTGAAAGGTGC

4060       4070       4080       4090       4100       4110       4120       4130       4140       4150       4160       4170       4180       4190       4200
GTTGAAGTGTTGGTATGTATGTGTTTTAAAGTATTGAAAACCCTTAAAATTGGTTGCACAGAAAAACCCCATCTGTTAAAGTTATAAGTGACTAAACAAATAACTAAATAGATGGGGGTTTCTTTTAATATTATGTGTCCTAATAGTAGC

4210       4220       4230       4240       4250       4260       4270       4280       4290       4300       4310       4320       4330       4340       4350
ATTTATTCAGATGAAAAATCAAGGGTTTTAGTGGACAAGACAAAAAGTGGAAAAGTGAGACCATGGAGAGAAAAGAAAATCGCTAATGTTGATTACTTTGAACTTCTGCATATTCTTGAATTTAAAAAGGCTGAAAGAGTAAAAGATTGT

4360       4370       4380       4390       4400       4410       4420       4430       4440       4450       4460       4470       4480       4490       4500
GCTGAAATATTAGAGTATAAACAAAATCGTGAAACAGGCGAAAGAAAGTTGTATCGAGTGTGGTTTTGTAAATCCAGGCTTTGTCCAATGTGCAACTGGAGGAGAGCAATGAAACATGGCATTCAGTCACAAAAGGTTGTTGCTGAAGTT

4510       4520       4530       4540       4550       4560       4570       4580       4590       4600       4610       4620       4630       4640       4650
ATTAAACAAAAGCCAACAGTTCGTTGGTTGTTTCTCACATTAACAGTTAAAAATGTTTATGATGGCGAAGAATTAAATAAGAGTTTGTCAGATATGGCTCAAGGATTTCGCCGAATGATGCAATATAAAAAAATTAATAAAAATCTTGTT

4660       4670       4680       4690       4700       4710       4720       4730       4740       4750       4760       4770       4780       4790       4800
GGTTTTATGCGTGCAACGGAAGTGACAATAAATAATAAAGATAATTCTTATAATCAGCACATGCATGTATTGGTATGTGTGGAACCAACTTATTTTAAGAATACAGAAAACTACGTGAATCAAAAACAATGGATTCAATTTTGGAAAAAG

4810       4820       4830       4840       4850       4860       4870       4880       4890       4900       4910       4920       4930       4940       4950
GCAATGAAATTAGACTATGATCCAAATGTAAAAGTTCAAATGATTCGACCGAAAAATAAATATAAATCGGATATACAATCGGCAATTGACGAAACTGCAAAATATCCTGTAAAGGATACGGATTTTATGACCGATGATGAAGAAAAGAAT

4960       4970       4980       4990       5000       5010       5020       5030       5040       5050       5060       5070       5080       5090       5100
TTGAAACGTTTGTCTGATTTGGAGGAAGGTTTACACCGTAAAAGGTTAATCTCCTATGGTGGTTTGTTAAAAGAAATACATAAAAAATTAAACCTTGATGACACAGAAGAAGGCGATTTGATTCATACAGATGATGACGAAAAAGCCGAT

5110       5120       5130       5140       5150       5160       5170       5180       5190       5200       5210       5220       5230       5240       5250
GAAGATGGATTTTCTATTATTGCAATGTGGAATTGGGAACGGAAAAATTATTTTATTAAAGAGTAGTTCAACAAACGGGCCAGTTTGTTGAAGATTAGATGCTATAATTGTTATTAAAAGGATTGAAGGATGCTTAGGAAGACGAGTTAT

5260       5270       5280       5290       5300       5310       5320       5330       5340       5350       5360       5370       5380       5390       5400
TAATAGCTGAATAAGAACGGTGCTCTCCAAATATTCTTATTTAGAAAAGCAAATCTAAAATTATCTGAAAAGGGAATGAGAATAGTGAATGGACCAATAATAATGACTAGAGAAGAAAGAATGAAGATTGTTCATGAAATTAAGGAACGA

5410       5420       5430       5440       5450       5460       5470       5480       5490       5500       5510       5520       5530       5540       5550
ATATTGGATAAATATGGGGATGATGTTAAGGCTATTGGTGTTTATGGCTCTCTTGGTCGTCAGACTGATGGGCCCTATTCGGATATTGAGATGATGTGTGTCATGTCAACAGAGGAAGCAGAGTTCAGCCATGAATGGACAACCGGTGAG

5560       5570       5580       5590       5600       5610       5620       5630       5640       5650       5660       5670       5680       5690       5700
TGGAAGGTGGAAGTGAATTTTGATAGCGAAGAGATTCTACTAGATTATGCATCTCAGGTGGAATCAGATTGGCCGCTTACACATGGTCAATTTTTCTCTATTTTGCCGATTTATGATTCAGGTGGATACTTAGAGAAAGTGTATCAAACT

5710       5720       5730       5740       5750       5760       5770       5780       5790       5800       5810       5820       5830       5840       5850
GCTAAATCGGTAGAAGCCCAAACGTTCCACGATGCGATTTGTGCCCTTATCGTAGAAGAGCTGTTTGAATATGCAGGCAAATGGCGTAATATTCGTGTGCAAGGACCGACAACATTTCTACCATCCTTGACTGTACAGGTAGCAATGGCA

5860       5870       5880       5890       5900       5910       5920       5930       5940       5950       5960       5970       5980       5990       6000
GGTGCCATGTTGATTGGTCTGCATCATCGCATCTGTTATACGACGAGCGCTTCGGTCTTAACTGAAGCAGTTAAGCAATCAGATCTTCCTTCAGGTTATGACCATCTGTGCCAGTTCGTAATGTCTGGTCAACTTTCCGACTCTGAGAAA

6010       6020       6030       6040       6050       6060       6070       6080       6090       6100       6110       6120       6130       6140       6150
CTTCTGGAATCGCTAGAGAATTTCTGGAATGGGATTCAGGAGTGGACAGAACGACACGGATATATAGTGGATGTGTCAAAACGCATACCATTTTGAACGATGACCTCTAATAATTGTTAATCATGTTGGTTACGTATTTATTAACTTCTC

6160       6170       6180       6190       6200       6210       6220       6230       6240       6250       6260       6270       6280       6290       6300
CTAGTATTAGTAATTATCATGGCTGTCATGGCGCATTAACGGAATAAAGGGTGTGCTTAAATCGGGCCATTTTGCGTAATAAGAAAAAGGATTAATTATGAGCGAATTGAATTAATAATAAGGTAATAGATTTACATTAGAAAATGAAAG
```

FIGURE 17 (cont'd)

Cullen, Hopkins & Rheaume

PATENT AGENTS

```
      6310       6320       6330       6340       6350       6360       6370       6380       6390       6400       6410       6420       6430       6440       6450
GGGATTTTATGCGTGAGAATGTTACAGTCTATCCCGGCATTGCCAGTCGGGGATATTAAAAAGAGTATAGGTTTTTATTGCGATAAACTAGGTTTCACTTTGGTTCACCATGAAGATGGATTCGCAGTTCTAATGTGTAATGAGGTTCGG

      6460       6470       6480       6490       6500       6510       6520       6530       6540       6550       6560       6570       6580       6590       6600
ATTCATCTATGGGAGGCAAGTGATGAAGGCTGGCGCTCTCGTAGTAATGATTCACCGGTTTGTACAGGTGCGGAGTCGTTTATTGCTGGTACTGCTAGTTGCCGCATTGAAGTAGAGGGAATTGATGAATTATATCAACATATTAAGCCT

      6610       6620       6630       6640       6650       6660       6670       6680       6690       6700       6710       6720       6730       6740       6750
TTGGGCATTTTGCACCCCAATACATCATTAAAAGATCAGTGGTGGGATGAACGAGACTTTGCAGTAATTGATCCCGACAACAATTTGATTAGCTTTTTTCAACAAATAAAAAGCTAAAATCTATTATTAATCTGTTCAGCAATCGGGCGC

      6760       6770       6780       6790       6800       6810       6820       6830       6840       6850       6860       6870       6880       6890       6900
GATTGCTGAATAAAAGATACGAGAGACCTCTCTTGTATCTTTTTTATTTTGAGTGGTTTTGTCCGTTACACTAGAAAACCGAAAGACAATAAAAATTTTATTCTTGCTGAGTCTGGCTTTCGGTAAGCTAGACAAAACGGACAAAATAAA

      6910       6920       6930       6940       6950       6960       6970       6980       6990       7000       7010       7020       7030       7040       7050
AATTGGCAAGGGTTTAAAGGTGGAGATTTTTTGAGTGATCTTCTCAAAAAATACTACCTGTCCCTTGCTGATTTTTAAACGAGCACGAGAGCAAAACCCCCCTTTGCTGAGGTGGCAGAGGGCAGGTTTTTTTGTTTCTTTTTTCTCGTA

      7060       7070       7080       7090       7100       7110       7120       7130       7140       7150       7160       7170       7180       7190       7200
AAAAAAAGAAAGGTCTTAAAGGTTTTATGGTTTTGGTCGGCACTGCCGACAGCCTCGCAGGACACACACTTTATGAATATAAAGTATAGTGTGTTATACTTTACTTGGAAGTGGTTGCCGGAAAGAGCGAAAATGCCTCACATTTGTGCC

      7210       7220       7230       7240       7250       7260       7270       7280       7290       7300       7310       7320       7330
ACCTAAAAAGGAGCGATTTACATATGAGTTATGCAGTTTGTAGAATGCAAAAAGTGAAATCAGGGGGATCCTCTAGAGTCGAGCTCAAGCTAGCTTGGTACGTACCAGATCTGAGATCACGCGTTCTAGAGGTCGA
```

FIGURE 17 (cont'd)

Cpley, Hoskin & Haworth

PATENT AGENTS



FIGURE 18

PATENT AGENTS



pGB/IL-313

Sequence;

S.D.

Hpall promoter-AAAGGAGCGATTTACAT ATG AGT
met ser

TAT GCA GTT TGT AGA ATG CAA AAA GTG
tyr ala val cys arg met gln lys val

S.D.

AAA TCA GGG GGA TCC AAG GAG GTG ATC
lys ser gly gly ser lys glu val ile

TAG AGT CGA CATG...pIL-3
stop met

FIGURE 19

PATENT AGENTS



FIGURE 20

PATENT AGENTS


HindIII
XhoI
HpaI
XbaI
SacII
romoter αfl IL-3 te
lactase pro
XbaI
G418r
pUC 19
ndIII

FIGURE 2

```
      4466       4476       4486       4496       4506       4516       4526       4536       4546       4556
CCGCGGGGAT CGAGTCATAA AATAGTAACC TTCTAATGCG TATCTATTGA CTACCAACCA TTAGTGTGGT TGCAGAAGGC GGAATTCTCC CTTCTTCGAA

      4566       4576       4586       4596       4606       4616       4626       4636       4646       4656
TTCAGCTTGC TTTTCATTTT TATTTTCCAT TTTTCAGTTT TTGTTTGTGT CGAATTTAGC CAGTTGCTTC TCCAAGATGA AAAAACCCCT GCGCAGTTTC

      4666       4676       4686       4696       4706       4716       4726       4736       4746       4756
TGTGTCGCAA GATCCTAATC GACTTTTCCA CCCCCCACAA AAGTAAATGT TTCTTTGTTA CATTCGCGTG GGTAGCTAGC TCCCCGAATC TCAAACGACT

      4766       4776       4786       4796       4806       4816       4826       4836       4846       4856
TAGGGACTGC ACTACATCAG AGTGTGTTCA CCTGGTTTGC TGCCTGGTTT GAAAGAAAAG AGCGGGAACT CGCGGGTTCC CGGCGAATAA TCATGCGATA

      4866       4876       4886       4896       4906       4916       4926       4936       4946       4956
GTCCTTTGGC CTTCCAAGTC GCATGTAGAG TAGACAACAG ACAGGGAGGG CAGGAAGGAT CTTTCACTGA GATCCTGTAT CTTGTTGGGT AAGTCGGATG

      4966       4976       4986       4996       5006       5016       5026       5036       5046       5056
AAAGGGGAAT CGTATGAGAT TGGAGAGGAT GCGGAAGAGG TAACGCCTTT TGTTAACTTG TTTAATTATT ATGGGGCAGG CGAGAGGGGG AGGAATGTAT

      5066       5076       5086       5096       5106       5116       5126       5136       5146       5156
GTGTGTGAGG CGGGCGACAC GGAGCCATCC AGGCCAGGTA GAAATAGAGA AAGCCGAATG TTAGACAATA TGGCAGCGTA GTAGAGTAGG TAGGTAGGCA

      5166       5176       5186       5196       5206       5216       5226       5236       5246       5256
AGTACTGCTA GCAAAGAGGA GAAGGGTAAG CTCACTCTTC GCATTCCACA CCGTTAGTGT GTCAGTTTAG ACAAAAAAAC AACTACTATA CCAATTAGTA

      5266       5276       5286       5296       5306       5316       5326       5336       5346       5356
GACTGTGAAC TGACTTTTGG AACGGCTTTT CGGACTGCGA TTATTCGTGA GGAATCAAGG TAGGAATTTG GTCATATTTA CGGACAACAG TGGGTGATTC

      5366       5376       5386       5396       5406       5416       5426       5436       5446       5456
CCATATGGAG TAGGAAAAGG AGATCATGGT ATCCTCAGAT ATGTTGCGGA ATTCTGTTCA CCGCAAAGTT CAGGGTGCTC TGGTGGGTTT CGGTTGGTCT

      5466       5476       5486       5496       5506       5516       5526       5536       5546       5556
TTGCTTTGCT TCTCCCTTGT CTTGCATGTT AATAATAGCC TAGCCTGTGA GCCGAAACTT AGGGTAGGCT TAGTGTTGGA ACGTACATAT GTATCACGTT

      5566       5576       5586       5596       5606       5616       5626       5636       5646       5656
GACTTGGTTT AACCAGGCGA CCTGGTAGCC AGCCATACCC ACACACGTTT TTTGTATTCT TCAGTATAGT TGTGAAAAGT GTAGCGGAAA TATGTGGTCC

      5666       5676       5686       5696       5706       5716       5726       5736       5746       5756
GAGCAACAGC GTCTTTTTCT AGTAGTGCGG TCGGTTACTT GGTTGACATT GGTATTTGGA CTTTGTTGCT ACACCATTCA CTACTTGAAG TCGAGTGTGA

      5766       5776       5786       5796       5806       5816       5826       5836       5846       5856
AGGGTATGAT TTCTAGTGGT GAACAGCTTT AGTTACGTAA TGTTTTCATT GCTGTTTTAC TTGAGATTTC GATTGAGAAA AAGGTATTTA ATAGCTCGAA

      5866       5876       5886       5896       5906       5916       5926       5936       5946       5956
TCAATGTGTT ATCATTGTGA AGATGTTCTT CCCTAACTCG AAAGGTATAT GAGGCTTGTG TTTCTTAGGA GAATTATTAT TCTTTTGTTA TGTTGCGCTT

      5966       5976       5986       5996       6006       6016       6026       6036       6046       6056
GTAGTTGGAA AAGGTGAAGA GACAAAAGCT TAACACTTGA AATTTAGGAA AGAGCAGAAT TTGGCAAAAA AAATAAAAAA AAAATAAACA CGTCGACTTG

      6066       6076       6086       6096       6106       6116       6126       6136       6146       6156
TGAGCGGATA ACAATCGACA CATACTCATC GAGAACTGAA AGATATGAGA TTTCCATCGA TTTTTACTGC AGTTTTATTC GCAGCATCCT CCGCATTAGC

      6166       6176       6186       6196       6206       6216       6226       6236       6246       6256
TGCTCCAGTC AACACTACAA CAGAAGATGA AACGGCACAA ATTCCGGCTG AAGCTGTCAT CGGTTACTTA GATTTAGAAG GGGATTTCGA TGTTGCTGTT

      6266       6276       6286       6296       6306       6316       6326       6336       6346       6356
TTGCCATTTT CCAACAGCAC AAATAACGGG TTATTGTTTA TAAATACTAC TATTGCCAGC ATTGCTGCTA AAGAAGAAGG GGTATCTCTA GATAAAAGAG

      6366       6376       6386       6396       6406       6416       6426       6436       6446       6456
CTCCCATGAC CCAGACAACG CCCTTGAAGA CAAGCTGGGT TAACTGCTCT AACATGATCG ATGAAATTAT AACACACTTA AAGCAGCCAC CTTTGCCTTT

      6466       6476       6486       6496       6506       6516       6526       6536       6546       6556
GCTGGACTTC AACAACCTCA ATGGGGAAGA CCAAGACATT CTGATGGAAA ATAACCTTCG AAGGCCAAAC CTGGAGGCAT TCAACCAGGC TGTCAAGAGT

      6566       6576       6586       6596       6606       6616       6626       6636       6646       6656
TTACAGAACG CATCAGCAAT TGAGAGCATT CTTAAAAATC TCCTGCCATG TCTGCCCCTG GCCACGGCCG CACCCACGCG ACATCCAATC CATATCAAGG

      6666       6676       6686       6696       6706       6716       6726       6736       6746       6756
ACGGTGACTG GAATGAATTC CGGAGGAAAC TGACGTTCTA TCTGAAAACC CTTGAGAATG CGCAGGCTCA ACAGACGACT TTGAGCCTCG CGATCTTTTG

      6766       6776       6786       6796       6806       6816       6826       6836       6846       6856
AGTCCAACGT CCAGCTCGTT CTCTGGGCCT TCTCACCACA GAGCCTCGGG ACATCAAAAA CAGCAGAACT TCTGAAACCT CTGGGTCATC TCTCACACAT

      6866       6876       6886       6896       6906       6916       6926       6936       6946       6956
TCCAGGACCA GAAGCATTTC ACCTTTTCCT GCGGCATCAG ATGAATTGTT AATTATCTAA TTTCTGAAAT GTGCAGCTCC CATTTGGCCT TGTGCGGTTG

      6966       6976       6986       6996       7006       7016       7026       7036       7046       7056
TGTTCTCATT TTTATCCCAT TGAGACTATT TATTTATGTA TGTATGTATT TATTTATTTA TTGCCTGGAG TGTGAACTGT ATTTATTTTA GCAGAGGAGC

      7066       7076       7086       7096       7106       7116       7126       7136       7146       7156
CATGTCCTGC TGCTTCTGCA AAAAACTCAG AGTGGGGTGG GGAGCATGTT CATTTGTACC TCGAGAATTT ATACTTAGAT AAGTATGTAC TTACAGGTAT

      7166       7176       7186       7196
ATTTCTATGA GATACTGATG TATACATGCA TGATAATATT TAAAGCTT
```

FIGURE 22

Colin Hooper, Hines

PATENT AGENTS

```
      4466       4476       4486       4496       4506       4516       4526       4536       4546       4556
CCGCGGGGAT CGACTCATAA AATAGTAACC TTCTAATGCG TATCTATTGA CTACCAACCA TTAGTGTGGT TGCAGAAGGC GGAATTCTCC CTTCTTCGAA

      4566       4576       4586       4596       4606       4616       4626       4636       4646       4656
TTCAGCTTGC TTTTCATTTT TATTTTCCAT TTTTCAGTTT TTGTTTGTGT CGAATTTAGC CAGTTGCTTC TCCAAGATGA AAAAACCCCT GCGCAGTTTC

      4666       4676       4686       4696       4706       4716       4726       4736       4746       4756
TGTGTCGCAA GATCCTAATC GACTTTTCCA CCCCCCACAA AAGTAAATGT TTCTTTGTTA CATTCGCGTG GGTAGCTAGC TCCCCGAATC TCAAAGGACT

      4766       4776       4786       4796       4806       4816       4826       4836       4846       4856
TAGGGACTGC ACTACATCAG AGTGTGTTCA CCTGGTTTGC TGCCTGGTTT GAAAGAAAAG AGCGGGAACT CGCGGGTTCC CGGCGAATAA TCATGCGATA

      4866       4876       4886       4896       4906       4916       4926       4936       4946       4956
GTCCTTTGGC CTTCCAAGTC GCATGTAGAG TAGACAACAG ACAGGGAGGG CAGGAAGGAT CTTTCACTGA GATCCTGTAT CTTGTTGGGT AAGTCGGATG

      4966       4976       4986       4996       5006       5016       5026       5036       5046       5056
AAAGGGGAAT CGTATGAGAT TGGAGAGGAT GCGGAAGAGG TAACGCCTTT TGTTAACTTG TTTAATTATT ATGGGGCAGG CGAGAGGGGG AGGAATGTAT

      5066       5076       5086       5096       5106       5116       5126       5136       5146       5156
GTGTGTGAGG CGGGCGAGAC GGAGCCATCC AGGCCAGGTA GAAATAGAGA AAGCCGAATG TTAGACAATA TGGCAGCGTA GTAGAGTAGG TAGGTAGGCA

      5166       5176       5186       5196       5206       5216       5226       5236       5246       5256
AGTACTGCTA GCAAAGAGGA GAAGGGTAAG CTCACTCTTC GCATTCCACA CCGTTAGTGT GTCAGTTTAG ACAAAAAAAC AACTACTATA CCAATTAGTA

      5266       5276       5286       5296       5306       5316       5326       5336       5346       5356
GACTGTGAAC TGACTTTTGG AACGGCTTTT CGGACTGCGA TTATTCGTGA GGAATCAAGG TAGGAATTTG GTCATATTTA CGGACAACAG TGGGTGATTC

      5366       5376       5386       5396       5406       5416       5426       5436       5446       5456
CCATATGGAG TAGGAAAACG AGATCATGGT ATCCTCAGAT ATGTTGCGGA ATTCTGTTCA CCGCAAAGTT CAGGGTGCTC TGGTGGGTTT CGGTTGGTCT

      5466       5476       5486       5496       5506       5516       5526       5536       5546       5556
TTGCTTTGCT TCTCCCTTGT CTTGCATGTT AATAATAGCC TAGCCTGTGA GCCGAAACTT AGGGTAGGCT TAGTGTTGGA ACGTACATAT GTATCACGTT

      5566       5576       5586       5596       5606       5616       5626       5636       5646       5656
GACTTGGTTT AACCAGGCGA CCTGGTAGCC AGCCATACCC ACACACGTTT TTTGTATTCT TCAGTATAGT TGTGAAAAGT GTAGCGGAAA TATGTGGTCC

      5666       5676       5686       5696       5706       5716       5726       5736       5746       5756
GAGCAACAGC GTCTTTTTCT AGTAGTGCGG TCGGTTACTT GGTTGACATT GGTATTTGGA CTTTGTTGCT ACACCATTCA CTACTTGAAG TCGAGTGTGA

      5766       5776       5786       5796       5806       5816       5826       5836       5846       5856
AGGGTATGAT TTCTAGTGGT GAACACCTTT AGTTACGTAA TGTTTTCATT GCTGTTTTAC TTGAGATTTC GATTGAGAAA AAGGTATTTA ATAGCTCGAA

      5866       5876       5886       5896       5906       5916       5926       5936       5946       5956
TCAATGTGTT ATCATTGTGA AGATGTTCTT CCCTAACTCG AAAGGTATAT GAGGCTTGTG TTTCTTAGGA GAATTATTAT TCTTTTGTTA TGTTGCGCTT

      5966       5976       5986       5996       6006       6016       6026       6036       6046       6056
GTAGTTGGAA AAGGTGAAGA GACAAAAGCT TAACACTTGA AATTTAGGAA AGAGCAGAAT TTGGCAAAAA AAATAAAAAA AAAATAAACA CGTCGACTTG

      6066       6076       6086       6096       6106       6116       6126       6136       6146       6156
TGAGCGGATA ACACTCGAGG GATCTTCATT ATGAAATTCT CTACTATATT AGCCGCATCT ACTGCTTTAA TTTCCGTTGT TATGGCTGCT CCAGTTTCTA

      6166       6176       6186       6196       6206       6216       6226       6236       6246       6256
CCGAAACTGA CATCGACGAT CTTCCAATTT CGGTTCCAGA AGAAGCCTTG ATTGGATTCA TTGACTTAAC CGGGGATGAA GTTTCCTTGT TGCCTGTTAA

      6266       6276       6286       6296       6306       6316       6326       6336       6346       6356
TAACGGAACC CACACTGGTA TTCTATTCTT AAACACCACC ATCGCTGAAG CTGCTTTCGC TGACAAGGAT GATTTGAAGA AGCGCGCTCC CATGACCCAG

      6366       6376       6386       6396       6406       6416       6426       6436       6446       6456
ACAACGCCCT TGAAGACAAG CTGGGTTAAC TGCTCTAACA TGATCGATGA AATTATAACA CACTTAAAGC AGCCACCTTT GCCTTTGCTG GACTTCAACA

      6466       6476       6486       6496       6506       6516       6526       6536       6546       6556
ACCTCAATGG GGAAGACCAA GACATTCTGA TGGAAAATAA CCTTCGAAGG CCAAACCTGG AGGCATTCAA CAGGGCTGTC AAGAGTTTAC AGAACGCATC

      6566       6576       6586       6596       6606       6616       6626       6636       6646       6656
AGCAATTGAG AGCATTCTTA AAAATCTCCT GCCATGTCTG CCCCTGGCCA CGGCCGCACC CACGCGACAT CCAATCCATA TCAAGGACGG TGACTGGAAT

      6666       6676       6686       6696       6706       6716       6726       6736       6746       6756
GAATTCCGGA GGAAACTGAC GTTCTATCTG AAAACCCTTG AGAATGCGCA GGCTCAACAG ACGACTTTGA GCCTCGCGAT CTTTTGAGTC CAACGTCCAG

      6766       6776       6786       6796       6806       6816       6826       6836       6846       6856
CTCGTTCTCT GGGCCTTCTC ACCACAGAGC CTCGGGACAT CAAAAACAGC AGAACTTCTG AAACCTCTGG GTCATCTCTC ACACATTCCA GGACCAGAAG

      6866       6876       6886       6896       6906       6916       6926       6936       6946       6956
CATTTCACCT TTTCCTGCGG CATCAGATGA ATTGTTAATT ATCTAATTTC TGAAATGTGC AGCTCCCATT TGGCCTTGTG CGGTTGTGTT CTCATTTTTA

      6966       6976       6986       6996       7006       7016       7026       7036       7046       7056
TCCCATTGAG ACTATTTATT TATGTATGTA TGTATTTATT TATTTATTGC CTGGAGTGTG AACTGTATTT ATTTTAGCAG AGGAGCCATG TCCTGCTGCT

      7066       7076       7086       7096       7106       7116       7126       7136       7146       7156
TCTGCAAAAA ACTCAGAGTG GGGTGGGGAG CATGTTCATT TGTACCTCGA GAATTTATAC TTAGATAAGT ATGTACTTAC AGGTATATTT CTATGAGATA

      7166       7176       7186
CTGATGTATA CATGCATGAT AATATTTAAA GCTT
```

FIGURE 23

PATENT AGENTS

```
        10         20         30         40         50         60         70         80         90        100
TCGAATTTGC GGGGAGAAGA TGGATCTATG CTAAATCTAA ATAGGCATTT GAAAAACGAC GACGAGTTAC ACGACATATC GCCATCTTTA AATGAGCAAC

       110        120        130        140        150        160        170        180        190        200
CACACTGGGA CCTCATAGAG GACGGGTCTC GCTGGAGTAA ATTTTTCAAC GGGATAATTA AGACGACAAG AAGGTTCACG AAATCTTTAA TGAGGTCTTT

       210        220        230        240        250        260        270        280        290        300
AGTCAGAGGC AGGAACAGCC GTCAAGGGGG CATAAGACTA CGGTCATCCC CATCTGCCTC TTCGTCCAGC CTTGCCAACA GGGAGTTCTT CAGAGACATG

       310        320        330        340        350        360        370        380        390        400
GAGGCTCAAA ACGAAATTAT TGACAGCCTA GACATCAATA GTCATACAAC AGAAAGCGAC CACCCAACTT TGGCTGATAA TAGCGTATAA ACAATGCATA

       410        420        430        440        450        460        470        480        490        500
CTTTGTACGT TCAAAATACA ATGCAGTAGA TATATTTATG CATATTACAT ATAATACATA TCACATAGGA AGCAACAGGC GCGTTGGACT TTTAATTTTC

       510        520        530        540        550        560        570        580        590        600
GAGGACCGCG AATCCTTACA TCACACCCAA TCCCCCACAA GTGATCCCCC ACACACCATA GCTTCAAAAT GTTTCTACTC CTTTTTTACT CTTCCAGATT

       610        620        630        640        650        660        670        680        690        700
TTCTCGGACT CCGCGCATCG CCGTACCACT TCAAAACACC CAAGCACAGC ATACTAAATT TCCCCTCTTT CTTCCTCTAG GGTGTCGTTA ATTACCCGTA

       710        720        730        740        750        760        770        780        790        800
CTAAAGGTTT GGAAAAGAAA AAAGAGACCG CCTCGTTTCT TTTTCTTCGT CGAAAAAGGC AATAAAAATT TTTATCACGT TTCTTTTTCT TGAAAATTTT

       810        820        830        840        850        860        870        880        890        900
TTTTTTTGAT TTTTTTCTCT TTCGATGACC TCCCATTGAT ATTTAAGTTA ATAAACGGTC TTCAATTTCT CAAGTTTCAG TTTCATTTTT CTTGTTCTAT

       910        920        930        940        950        960        970        980        990       1000
TACAACTTTT TTTACTTCTT GCTCATTAGA AAGAAAGCAT AGCAATCTAG TCGACAGATC TCTCGAGTGC TTTTGTGCGC GTATGTTTAT GTATGTACCT

      1010       1020       1030       1040       1050       1060       1070       1080       1090       1100
CTCTCTCTAT TTCTATTTTT AAACCACCCT CTCAATAAAA TAAAAATAAT AAAGTATTTT TAAGGAAAAG ACGTGTTTAA GCACTGACTT TATCTACTTT

      1110
TTGTACGTCT AGA
```

FIGURE 24

PATENT AGENTS